CN112552401B - 抗pd1抗体及其作为治疗剂与诊断剂的用途 - Google Patents

抗pd1抗体及其作为治疗剂与诊断剂的用途 Download PDF

Info

Publication number
CN112552401B
CN112552401B CN202011322092.7A CN202011322092A CN112552401B CN 112552401 B CN112552401 B CN 112552401B CN 202011322092 A CN202011322092 A CN 202011322092A CN 112552401 B CN112552401 B CN 112552401B
Authority
CN
China
Prior art keywords
ser
val
gly
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011322092.7A
Other languages
English (en)
Other versions
CN112552401A (zh
Inventor
宋兢
李康
张彤
徐兰兰
刘琦
彭浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Baiji Shenzhou Biopharmaceutical Co ltd
Original Assignee
Guangzhou Baiji Shenzhou Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Baiji Shenzhou Biopharmaceutical Co ltd filed Critical Guangzhou Baiji Shenzhou Biopharmaceutical Co ltd
Priority to CN202011322092.7A priority Critical patent/CN112552401B/zh
Publication of CN112552401A publication Critical patent/CN112552401A/zh
Application granted granted Critical
Publication of CN112552401B publication Critical patent/CN112552401B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明涉及抗PD1抗体及其作为治疗剂与诊断剂的用途。本发明提供特异性结合程序性死亡‑1(PD1、Pdcd‑1或CD279)、抑制免疫细胞中PD1介导的细胞信号传导及活性，并结合PD1的配体所需要的一套氨基酸残基的抗体，及这些抗体治疗或诊断由PD1介导的功能所调控的癌症、传染性疾病或其他病理病症的用途。

Description

抗PD1抗体及其作为治疗剂与诊断剂的用途
本申请是申请日为2013年09月13日、中国申请号为201380079581.6、发明名称为“抗PD1抗体及其作为治疗剂与诊断剂的用途”的发明申请的分案申请。
发明背景
程序性死亡-1(Programmed Death-1；PD-1，也称为CD279)是一种与CD28/CTLA4共同刺激/抑制受体家族相关的55KD受体蛋白质(Blank等人，2005Cancer ImmunolImmunother 54:307-314)。在小鼠及人类中克隆及表征了编码PD-1的基因及cDNA(Ishida等人，1992EMBO J 11:3887-3395；Shinohara等人，1994Genomics 23:704-706)。全长PD-1含有288个氨基酸残基(NCBI登录号：NP_005009)。它的胞外域由氨基酸残基1-167组成，而胞质C末端尾部包含残基191-288，该尾部具有两个假设性免疫调节基序，一个是基于免疫受体酪氨酸的抑制基序(ITIM；Vivier等人，1997Immunol Today 18:286-291)，一个是免疫受体酪氨酸转换基序(ITSM；Chemnitz等人，2004J Immunol 173:945-954)。
迄今为止，两个序列相关配体PD-L1(B7-H1)与PD-L2(B7-DC)已被鉴定为与PD-1特异性相互作用，诱导细胞内信号转导，该细胞内信号转导抑制CD3及CD28介导的T细胞激活(Riley,2009Immunol Rev 229:114-125)，继而削弱T细胞活性(例如，减少细胞增殖、IL-2与IFN-γ分泌，以及其他生长因子及细胞因子分泌)。
经常在诸如T细胞、B细胞、单核细胞及天然杀伤(NK)细胞等免疫细胞中发现PD-1的表达。PD-1很少在诸如肌肉、上皮、神经元组织等其他人类组织中表达。此外，高水平的PD-1表达常常与免疫细胞的激活关联。举例而言，当藉由植物血球凝集素(PHA)或佛波醇酯(12-O-十四酰基佛波醇-13-乙酸酯或TPA)激活人类T细胞系Jurkat时，在Western印迹中可见PD-1的表达上调(Vibharka等人，1997Exp Cell Res 232:25-28)。在被抗CD3抗体刺激后，在受刺激鼠类T淋巴细胞及B淋巴细胞中及在原代人类CD4+T细胞中观察到相同现象(Agata等人，1996Int Immunol 8:765-772；Bennett等人，2003J Immunol 170:711-118)。T效应细胞刺激后的PD-1表达增强使得朝耗竭及减少免疫活性方向再导向激活的T效应细胞。因此，PD-1介导的抑制信号在免疫耐受方面起到重要作用(Bour-Jordan等人，2011Immunol Rev 241:180-205)。
在各种涉及不同类型组织及器官的癌症方面，报告了肿瘤浸润淋巴细胞(TIL)中的PD-1表达及肿瘤细胞中的PD-1配体表达的增强，所述组织及器官诸如肺(Konishi等人，2004Clin Cancer Res 10:5094-5100)、肝(Shi等人，2008Int J Cancer 128:887-896；Gao等人，2009Clin Cancer Res 15:971-979)、胃(Wu等人，2006Acta Histochem 108:19-24)、肾(Thompson等人，2004Proc Natl Acad Sci 101:17174-17179；Thompson等人，2007ClinCancer Res 13:1757-1761)、乳腺(Ghebeh等人，2006Neoplasia 8:190-198)、卵巢(Hamanishi等人，2007Proc Natl Acad Sci 104:3360-3365)、胰腺(Nomi等人，2007ClinCancer Res 13:2151-2157)、黑素细胞(Hino等人，2010Cancer 116:1757-1766)及食道(Ohigashi等人，2005Clin Cancer Res 11:2947-2953)。更经常地，那些癌症中的PD-1及PD-L1增强表达与患者生存结果的不良预后关联。具有抑制异体移植癌细胞生长的PD-1基因敲除的转基因小鼠进一步阐明在癌症根治或耐受的免疫系统调控中PD-1信号传导的重要性(Zhang等人，2009Blood 114:1545-1552)。
PD-1信号传导上调不仅导致对癌生长的免疫耐受，而且导致人类中的病毒感染及扩充。流行性肝感染病毒HBV及HCV诱导肝细胞中的PD-1配体的过度表达及激活T效应细胞中的PD-1信号传导，从而引起T细胞耗竭及对病毒感染的耐受(Boni等人，2007J Virol81:4215-4225；Golden-Mason等人，2008J Immunol 180:3637-3641)。同样地，HIV感染常常藉由类似机制避开人类免疫系统。拮抗剂分子对PD-1信号传导的治疗性调控可从耐受中反转免疫细胞，并经再激活以根治癌症及慢性病毒感染(Blank等人，2005Cancer ImmunolImmunother 54:307-314；Okazaki等人，2007Int Immunol 19:813-824)。
发明概述
本发明提供PD-1的免疫抑制的方法及组合物。在一个方面中，本发明提供一种抗体抗原结合域，该抗体抗原结合域特异性结合人类PD-1，且包含具有选自序列编号11-22、31-42及59-63的序列的互补决定区(CDR)。
CDR可经历重组成为重链可变区(Vh)及轻链可变区(Vκ)，所述区分别包含(CDR-H1、CDR-H2及CDR-H3)及(CDR-L1、CDR-L2及CDR-L3)序列，且保持特异于PD-1的结合及/或功能性。
在特定实施方案中，域包含重链可变区(Vh)或轻链可变区(Vκ)，所述可变区包含：
在特定实施方案中，域包含重链可变区(Vh)及/或轻链可变区(Vκ)，所述可变区包含：
a)mu317 CDR-H1、CDR-H2及CDR-H3(序列编号11-13)；
CDR-L1、CDR-L2及CDR-L3(序列编号14-16)；
b)mu326 CDR-H1、CDR-H2及CDR-H3(序列编号17-19)；
CDR-L1、CDR-L2及CDR-L3(序列编号20-22)；
c)317-4B6 CDR-H1、CDR-H2及CDR-H3(序列编号31-33)；
CDR-L1、CDR-L2及CDR-L3(序列编号34-36)；
d)326-4A3 CDR-H1、CDR-H2及CDR-H3(序列编号37-39)；
CDR-L1、CDR-L2及CDR-L3(序列编号40-42)；
e)317-1CDR-H1、CDR-H2及CDR-H3(序列编号11、59、13)；
CDR-L1、CDR-L2及CDR-L3(序列编号14-16)；
f)317-4B2 CDR-H1、CDR-H2及CDR-H3(序列编号11、60、13)；
CDR-L1、CDR-L2及CDR-L3(序列编号61、15、16)；
g)317-4B5 CDR-H1、CDR-H2及CDR-H3(序列编号11、60、13)；
CDR-L1、CDR-L2及CDR-L3(序列编号61、15、16)；
h)317-4B6 CDR-H1、CDR-H2及CDR-H3(序列编号11、32、13)；
CDR-L1、CDR-L2及CDR-L3(序列编号61、15、16)；
i)326-1 CDR-H1、CDR-H2及CDR-H3(序列编号17、62、19)；
CDR-L1、CDR-L2及CDR-L3(序列编号20-22)；
j)326-3B1 CDR-H1、CDR-H2及CDR-H3(序列编号17、62、19)；
CDR-L1、CDR-L2及CDR-L3(序列编号20-22)；
k)326-3G1 CDR-H1、CDR-H2及CDR-H3(序列编号17、62、19)；及
CDR-L1、CDR-L2及CDR-L3(序列编号20-22)。
在特定实施方案中，域包含重链可变区(Vh)及轻链可变区(Vκ)，所述可变区包含：
(a)CDR-H1(序列编号31)、CDR-H2(序列编号12、32、59或60)及CDR-H3(序列编号33)，
CDR-L1(序列编号14、34或61)、CDR-L2(序列编号35)及CDR-L3(序列编号36)；或
(b)CDR-H1(序列编号37)、CDR-H2(序列编号18、38或62)及CDR-H3(序列编号39)，
CDR-L1(序列编号40)、CDR-L2(序列编号41)及CDR-L3(序列编号42)。
在特定实施方案中，域包含重链可变区(Vh)或轻链可变区(Vκ)，所述可变区包含：
在特定实施方案中，域包含重链可变区(Vh)及轻链可变区(Vκ)，所述可变区包含：
在特定实施方案中，域特异性结合PD1残基：(a)K45及I93(基于2008PNAS,105:10483进行AA编号；相当于序列编号2中的K58及I106)；或(b)I93、L95及P97(基于2008PNAS,105:10483进行AA编号；相当于序列编号2中的I106、L108及P110)。
在特定实施方案中，域诱导与HEK293/OS8/PD-L1细胞或与HEK293/OS8/PD-L2细胞共同培养的HuT78/PD-1细胞中的IL-2释放，及/或抑制与HEK293/PD-L1细胞或与HEK293/PD-L2细胞共同培养的HuT78/P3Z细胞中的IL-2分泌。
本发明还提供一种抗体IgG4重链效应器或恒定域，该效应器或恒定域包含序列编号83-88中的任一者，尤其是序列编号87或88。
本发明还提供包含专属PD-1结合域的抗体、F(ab)或F(ab)2。
本发明还提供抗体，所述抗体包含专属PD-1结合域及IgG4重链效应器或恒定域，该效应器或恒定域包含序列编号83-88中的任一者，尤其是序列编号87或88。
本发明还提供一种编码专属PD-1结合域的多核苷酸，尤其是cDNA序列。
本发明提供使用该专属域的方法，该方法藉由向确定患有癌症或病毒感染或确定另外需要PD-1拮抗作用的个人施用该域。
本发明还提供融合蛋白，所述融合蛋白包含：(a)融合至小鼠CD8α的C末端域(113-220)的抗人类CD3单抗OKT3的单链可变片段(scFv)(序列编号89)；或(b)融合至人类CD3ζ链的胞质域的人类PD-1的胞外域及跨膜域(序列编号90)。
本发明还提供使用该专属融合蛋白的方法，该方法包含用表达融合蛋白的细胞系检定、筛选或选择抗PD-1抗体。
附图简述
图1：PD-1/Fc(上图)及PD-1/His(下图)的示意性呈现。ECD：胞外域。L：接头。H：His标签。Fc：人类IgG4中的γ4Fc片段。N：N末端。C：C末端。
图2：在ELISA中结合至人类PD-1的鼠类单抗的剂量依赖型反应曲线。各图的左上角指示鼠类单抗。单抗317及517共享重链及轻链的可变区的高度同源性。藉由直接OD450读数指示结合信号强度。抗原PD-1/His以50微升的体积中增加浓度，至高达每孔70纳克来包被。在实施例1中描述该方法。
图3：藉由FACS分析产生的结合至活细胞上所表达的人类PD-1的鼠类单抗的剂量依赖型反应曲线。在各个小图上指示鼠类抗体代码及EC50。MFI代表荧光强度均值。使HuT78/PD-1细胞以每孔5x104个细胞悬浮于96孔板中用于FACS。如实施例1中所描述执行PD-1单抗结合至细胞表面靶点及FACS检测。
图4：用于检定抗PD-1单抗的功能活性的细胞共同培养系统的示意性表示。T细胞(CD4+或CD8+)表示HuT78/PD-1或PBMC中的原代T细胞。TCR：T细胞受体。N：细胞核。C：细胞质。
图5：与HEK293/OS8/PD-L1细胞共同培养的HuT78/PD-1细胞中鼠类单抗诱导的IL-2分泌的剂量依赖型反应曲线。基线：在所有受测试浓度下由mIgG所诱导的平均IL-2释放。顶线：基于Prizm Software回归计算所得的最高IL-2释放。
图6：(A)图示与细胞系HEK293/OS8/PD-L1共同培养的PBMC(供体19)中抗PD-1单抗所诱导的IFN-γ分泌的直方图。(B)图示与细胞系HEK293/OS8/PD-L1共同培养的PBMC(供体20)中抗PD-1单抗所诱导的IFN-γ分泌的直方图。
图7：(A)与(B)藉由共同培养效应细胞(NK92MI/PD-1)及靶细胞(HuT78/PD-1)所得的抗PD-1单抗的ADCC活性。由代表性实验的两个数据点计算均值。将单抗添加到10μg/ml的浓度。如实施例9中所描述执行实验。
图8：藉由ELISA(上图)及Western印迹(下图)定位抗PD-1单抗的结合表位。使用含有WT或Mt PD-1的条件培养基藉由ELISA及Western印迹评估结合活性。**指示单抗结合活性降低至WT PD-1的25-50％的AA残基。***指示单抗结合活性降低至WT PD-1的25％以下的AA残基。
图9：来自不同健康供体的原代人类PBMC中由人源化抗PD-1单抗所诱导的IFN-γ释放，原代人类PBMC与HEK293/OS8/PD-L1细胞共同培养。
图10：由人源化抗PD-1单抗hu317(A)及hu326(B)增强的NK92MI/PD-1细胞的细胞毒性。靶肺癌细胞SK-MES-1/PD-L1与效应细胞以1:2的(T比E)比率共同培养，以及如实施例12所述进行检定。
图11：三个治疗群组：媒剂(PBS)、人类IgG(huIgG)及抗PD-1单抗(hu317-1/IgG4mt2)中的个体肿瘤生长曲线。各个曲线表示肿瘤生长路径，藉由各小图右侧指示数字对负有肿瘤小鼠编代码。在第1天时接种Hep3B/OS8/PD-L1细胞(自肝细胞癌系Hep3B建立)，在第15天时植入PBMC，及在第18天、第28天及第38天时分别注射三剂hu317-1/IgG4mt2。在实施例12中描述方法。
发明详述
当被PD-1的配体PD-L1或PD-L2接合时，PD-1启动免疫细胞中的抑制性信号传导。在癌长出及病毒感染的情况下，PD-1信号传导的激活促进了免疫耐受，导致癌症或病毒感染细胞逃避免疫监视及癌症转移或病毒负荷增长。藉由治疗剂抑制PD-1介导的细胞信号传导可激活包括T细胞、B细胞及NK细胞在内的免疫细胞，并因此增强抑制癌细胞生长或病毒感染的免疫细胞功能，及恢复免疫监视及免疫记忆功能以治疗此类人类疾病。
本发明提供抗体，这些抗体的功能拮抗免疫细胞中配体诱导及PD-1介导的细胞信号传导。鼠类抗PD-1抗体经人源化为在框架区中高度类似于人类抗体。以经修饰的人类IgG4变体形式产生的全抗体在效应器功能及物理化学特性的方面中具有独特的特征集合。所揭露抗PD-1抗体适合于癌症治疗、控制病毒感染及机制上涉及加剧免疫耐受的其他人类疾病中的治疗用途。
定义
除非上下文另有指示，否则术语“抗体”是用于广义上，且具体覆盖抗体(包括全长单克隆抗体)及抗体片段，只要它们识别PD-1即可。抗体分子通常为单特异性，但也可描述为独特特异性、异种特异性或多特异性。抗体分子经由特异性结合位点结合至抗原上的特定抗原决定簇或表位。“抗体片段”包含全长抗体的一部分，大体而言为全长抗体的抗原结合或可变区。抗体片段的实例包括Fab、Fab'、F(ab')2及Fv片段；双抗体；线性抗体；单链抗体分子；及由抗体片段形成的多特异性抗体。
可藉由熟悉此项技术者已知的方法获得单克隆抗体(单抗)。请参看例如，Kohler等人(1975)；美国专利第4,376,110号；Ausubel等人(1987-1999)；Harlow等人(1988)；及Colligan等人(1993)。本发明的单抗可以是任何免疫球蛋白类别，包括IgG、IgM、IgE、IgA及上述的任何亚类。可在体外或体内培养产生单抗的杂交瘤。在体内产生中可获得高滴度的单抗，其中将来自个别杂交瘤中的细胞经腹膜内注射至小鼠(诸如原始致敏Balb/c小鼠)体内以产生含有高浓度所欲单抗的腹水液。可使用熟习此项技术者所熟知的柱层析法自此类腹水液或自培养物上清液中纯化同种型IgM或IgG的单抗。
“经分离多核苷酸”是指已与天然产生状态下位于侧翼的序列分开的多核苷酸区段或片段，例如已自正常邻接于片段的序列移除的DNA片段，例如在天然产生片段的基因组中邻接于片段的序列。因此，该术语包括(例如)并入载体中、并入自主复制质粒或病毒中或并入原核生物或真核生物的基因组DNA中的重组DNA，或作为独立于其他序列的单独分子存在(例如，作为cDNA或由PCR或限制酶消化产生的基因组或cDNA片段)的重组DNA。还包括如下重组DNA，该重组DNA为杂合基因中编码额外多肽序列的一部分。
“构建体”意谓任何重组多核苷酸分子(诸如质粒、粘粒、病毒、自主复制多核苷酸分子、噬菌体或线性或环状单链或双链DNA或RNA多核苷酸分子)，衍生自任何来源，能够基因组整合或自主复制，构成如下多核苷酸分子，其中已经以功能操作的方式连接(即，可操作地连接)一或多个多核苷酸分子。重组构建体通常会包含可操作地连接至转录起始调节序列的本发明的多核苷酸，这些序列会导引多核苷酸在所欲宿主细胞中的转录。可使用异源及非异源(即，内源)启动子两者导引本发明的核酸的表达。
“载体”是指任何重组多核苷酸构建体，该构建体可用于转化的目的(即，将异源DNA引入到宿主细胞中)。一种类型的载体为“质粒”，是指环状双链DNA环，可将额外DNA区段连接至该环中。另一类型的载体为病毒载体，其中可将额外DNA区段连接至病毒基因组中。某些载体能够在被引入到的宿主细胞中自主复制(例如，具有细菌复制起点的细菌载体及游离型哺乳动物载体)。在引入到宿主细胞中后，其他载体(例如，非游离型哺乳动物载体)整合至宿主细胞的基因组中，且因此与宿主基因组一起复制。此外，某些载体能够导引被操作性连接的基因的表达。本文将此类载体称为“表达载体”。
本文所使用的“表达载体”是指能够在转化、转染或转导至宿主细胞中时复制及表达感兴趣基因的核酸分子。表达载体包含一或多个表型选择标记及复制起点，以确保维护载体及以在需要的情况下于宿主内提供扩增。表达载体进一步包含启动子，以驱动多肽在细胞内的表达。适宜表达载体可为衍生自pBR322的质粒或各种pUC质粒，这些质粒为市售。其他表达载体可衍生自噬菌体、噬菌粒或粘粒表达载体。
本发明的额外实施方案
在特定实施方案中，本发明提供自筛选本文所揭露的鼠类杂交瘤克隆所鉴定的小鼠单克隆抗体。
在其他实施方案中，本发明提供以下多核苷酸及蛋白质序列的组合物：
a)编码鼠类单抗317的重链可变区的cDNA序列，序列编号3；
b)mu317_Vh或鼠类单抗317的重链可变区的蛋白质序列(序列编号4)；
c)编码鼠类单抗317的轻链可变区的cDNA序列，序列编号5；
d)mu317_Vκ或鼠类单抗317的轻链可变区的蛋白质序列(序列编号6)；
e)编码鼠类单抗326的重链可变区的cDNA序列，序列编号7；
f)mu326_Vh或鼠类单抗326的重链可变区的蛋白质序列(序列编号8)；
g)编码鼠类单抗326的轻链可变区的cDNA序列，序列编号9；
h)mu326_Vκ或鼠类单抗326的轻链可变区的蛋白质序列(序列编号10)。
在一个方面中，本发明提供包含互补决定区(CDR)序列的组合物，这些序列介导结合至靶抗原PD-1，包括mu317及mu326的CDR序列：
a)mu317重链的CDR1(mu317 H-CDR1)含有氨基酸序列GFSLTSYGVH(序列编号11)；
b)mu317 H-CDR2含有氨基酸序列VIWAGGSTNYNSALMS(序列编号12)；
c)mu317 H-CDR3含有氨基酸序列ARAYGNYWYIDV(序列编号13)；
d)mu317轻链的CDR1(mu317 L-CDR1)含有氨基酸序列KASQSVSNDVA(序列编号14)；
e)mu317 L-CDR2含有氨基酸序列YAFHRFT(序列编号15)；
f)mu317 L-CDR3含有氨基酸序列HQAYSSPYT(序列编号16)；
g)mu326 H-CDR1含有氨基酸序列GYTFTNYGMN(序列编号17)；
h)mu326 H-CDR2含有氨基酸序列WINNNNGEPTYAEEFKG(序列编号18)；
i)mu326 H-CDR3含有氨基酸序列ARDVMDY(序列编号19)；
j)mu326 L-CDR1含有氨基酸序列RASESVDNYGYSFMH(序列编号20)；
k)mu326 L-CDR2含有氨基酸序列RASNLES(序列编号21)；
l)mu326 L-CDR3含有氨基酸序列QQSKEYPT(序列编号22)。
在另一实施方案中，本发明提供包含源自鼠类单抗mu317及mu326的人源化单克隆抗体的序列的组合物，包括：
a)人源化单抗hu317-4B6包含作为序列编号24的重链可变区(Vh)的蛋白质序列，该重链可变区由以下编码：
b)hu317-4B6_Vh的cDNA(序列编号23)；
c)人源化单抗hu317-4B6还包含作为序列编号26的轻链可变区(Vκ)的蛋白质序列，该轻链可变区由以下编码：
d)hu317-4B6的cDNA(序列编号25)；
e)人源化单抗hu326-4A3包含作为序列编号28的Vh的蛋白质序列，该Vh由以下编码：
f)hu326-4A3-Vh的cDNA(序列编号27)；
g)人源化单抗hu326-4A3还包含作为序列编号30的Vκ的蛋白质序列，该Vκ由以下编码：
h)hu326-4A3_Vκ的cDNA(序列编号29)；
i)hu317-4B2_Vh的蛋白质序列(序列编号43)与hu317-4B2_Vκ的蛋白质序列(序列编号44)；
j)hu317-4B5_Vh的蛋白质序列(序列编号45)与hu317-4B5_Vκ的蛋白质序列(序列编号46)；
k)hu317-1_Vh的蛋白质序列(序列编号48)与编码hu317-1_Vh的cDNA(序列编号47)；
l)hu317-1_Vκ的蛋白质序列(序列编号50)与编码hu317-1_Vκ的cDNA(序列编号49)；
m)hu326-3B1_Vh的蛋白质序列(序列编号51)与hu326-3B1_Vκ的蛋白质序列(序列编号52)；
n)hu326-3G1_Vh的蛋白质序列(序列编号53)与hu326-3G1_Vκ的蛋白质序列(序列编号54)；
o)hu326-1_Vh的蛋白质序列(序列编号56)与编码hu326-1_Vh的cDNA(序列编号55)；
p)hu326-1_Vκ的蛋白质序列(序列编号58)与编码hu326-1_Vκ的cDNA(序列编号57)；
q)源自mu317的其他人源化单抗的蛋白质序列(序列编号63-74)；
r)源自mu326的其他人源化单抗的蛋白质序列(序列编号75-82)。
在一个方面中，本发明提供包含人源化单克隆抗体的CDR序列的组合物。在相同系列的人源化单抗(诸如hu317或hu326)中可共享CDRs(参看表15-16)。以下列出非冗余CDRs：
a)H-CDR1序列GFSLTSYGVH(序列编号31)，为所有人源化单抗hu317及mu317重链所共享；
b)H-CDR3序列ARAYGNYWYIDV(序列编号33)，为所有人源化单抗hu317及mu317重链所共享；
c)L-CDR1序列KSSESVSNDVA(序列编号34)，为所有人源化单抗hu317-4B2、hu317-4B5及hu317-4B6轻链所共享；
d)L-CDR2序列YAFHRFT(序列编号35)，为所有人源化单抗hu317及mu317轻链所共享；
e)L-CDR3序列HQAYSSPYT(序列编号36)，为所有人源化单抗hu317及mu317轻链所共享；
f)hu317-4B6_Vh中的H-CDR2序列VIYADGSTNYNPSLKS(序列编号32)；
g)hu317-4B2_Vh与hu317-4B5_Vh中的H-CDR2序列VIYAGGSTNYNPSLKS(序列编号60)；
h)hu317-1_Vh中的H-CDR2序列VIWAGGSTNYNPSLKS(序列编号59)；
i)hu317-1_Vk中的L-CDR1序列KASQSVSNDVA(序列编号11)；
j)H-CDR1序列GYTFTNYGMN(序列编号37)，为所有人源化单抗hu326及mu326重链所共享；
k)H-CDR3序列ARDVMDY(序列编号39)，为所有人源化单抗hu326及mu326重链所共享；
l)L-CDR1序列RASESVDNYGYSFMH(序列编号40)，为所有人源化单抗hu326及mu326轻链所共享；
m)L-CDR2序列RASNLES(序列编号41)，为所有人源化单抗hu326及mu326轻链所共享；
n)L-CDR3序列QQSKEYPT(序列编号42)，在为所有人源化单抗hu326及mu326轻链所共享；
o)hu326_4A3_Vh中的H-CDR2序列WINNNNAEPTYAQDFRG(序列编号38)；
p)hu326_1及其他hu317单抗的Vh中的H-CDR2序列WINNNNGEPTYAQGFRG(序列编号62)。
在另一方面中，本发明提供抗原上人源化抗PD-1单抗的特定结合表位及其功能用途。使PD-1中配体结合所需要的六个关键氨基酸(AA)残基个别突变，及使用突变体与野生型PD-1蛋白质评估结合表位。将突变使抗体结合明显削弱的残基视为关键或明显结合表位。单抗hu317-4B5及hu317-4B6的明显结合表位为K45及I93(基于2008PNAS,105:10483进行AA编号；相当于序列编号2中的K58及I106)；及单抗hu326-3B1及hu317-4A3的明显结合表位为I93、L95及P97(基于2008PNAS,105:10483进行AA编号；相当于序列编号2中的I106、L108及P110)。
在又一方面中，本发明提供包含重组人类IgG4变体的恒定区序列的组合物，该恒定区序列可连接至特定抗体(包括人源化抗PD-1单抗)的可变区，这些恒定区序列展示出优选的效应器功能及物理化学特性。序列如下：
IgG4mt10的恒定区序列(序列编号88)；
a)IgG4mt1的参考序列(序列编号83)；
b)IgG4mt2的参考序列(序列编号84)；
c)IgG4mt6的参考序列(序列编号85)；
d)IgG4mt8的参考序列(序列编号86)；
e)IgG4mt9的参考序列(序列编号87)。
在另一实施方案中，本发明提供检定抗PD-1抗体功能的方法，该方法使用表达重组融合蛋白OS8的质粒产生稳定细胞系HEK293/OS8/PD-L1或HEK293/OS8/PD-L2，该稳定细胞系共同表达OS8(一种T细胞激活分子)及PD-1配体。使用细胞系藉由共同培养接合T细胞及PBMCs，以评估抗PD-1单抗的功能性(参看实施例3及实施例4)。或者，使用表达重组融合蛋白P3Z的另一质粒产生稳定细胞系HuT78/P3Z，其中P3Z用作分子传感器及信号转导介体。当由PD-1配体接合P3Z时，P3Z会传导细胞内信号以激活HuT78细胞中的IL-2释放。这些系统可用于评估抗PD-1单抗的抑制效果(参看实施例3)。
在一个方面中，本发明提供包含重组融合蛋白的氨基酸序列的组合物，这些序列如下：
a)OS8的蛋白质序列(序列编号89)；
b)P3Z的蛋白质序列(序列编号90)。
在另一方面中，本发明提供产生表达本文所描述的重组融合蛋白的稳定细胞系的方法，及使用该系统定量检定抗PD-1单抗的功能活性的方法。
在另一实施方案中，本发明提供编码主题蛋白质的多核苷酸。可将多核苷酸可操作地连接至异源转录调节序列用于表达及可并入载体、细胞等中。
在另一实施方案中，本发明提供鼠类抗PD-1抗体及人源化型式的抗PD-1抗体，这些人源化型式的抗PD-1抗体包括hu317-4B6、hu317-4B5、hu317-4B2等及hu326-4A3、hu326-3B1、hu326-3G1等，这些抗体具有抑制PD-1介导的信号转导及激活免疫细胞的功能，这些功能触发包括细胞因子分泌及对靶细胞(诸如癌细胞)的细胞毒性的级联免疫反应，及提供这些抗体的此类功能用途。
在一个方面中，本发明提供激活表达PD-1的若干类型免疫细胞的人源化抗PD-1抗体，这些免疫细胞包括人类T细胞、NK细胞及PBMCs，这些免疫细胞的功能为放大免疫应答信号，调动免疫系统，及充当免疫效应细胞以便清除癌细胞及病毒感染，及提供这些抗体的此类功能用途。
在另一方面中，将人源化抗PD-1单抗用作治疗剂来治疗涉及由PD-1介导的细胞内信号传导抑制免疫细胞而导致病情恶化的人类疾病，尤其是癌症及病毒感染。
本发明的组合物对于治疗癌症、神经退化性疾病及传染性疾病(尤其是病毒性疾病)及人类PD-1的不适宜或不利表达是其病因学或病理学的组份的其他疾患是有用的。因此，本发明提供用专属抗PD-1蛋白质在有需要的受试者中治疗癌症或抑制肿瘤发展的方法。本发明进一步提供专属多核苷酸制造在受试者中治疗癌症或抑制肿瘤发展的药剂中的用途。
本发明包括所叙述特定实施方案的所有组合。本发明的进一步实施方案及可应用性的完整范畴将自下文所提供的详细描述变得显而易见。然而，应理解，尽管详细描述及特定实施例指示本发明的优选实施方案，但仅以说明的方式提供这些描述及实施例，因为本发明的精神及范畴内的各种改变及修改将自此详细描述对熟悉此项技术者变得显而易见。出于所有目的，包括引文在内的本文所引用的所有公开物、专利及专利申请将以引用的方式全部并入本文。
实施例
实施例1：抗PD-1单克隆抗体的产生
基于常规杂交瘤融合技术(Kohler与Milstein 1976Eur J Immunol 6:511-519；de St Groth与Sheidegger 1980，J Immunol Methods 35:1-21；Mechetner 2007MethodsMol Biol378:1-13)并略作修改产生抗PD-1单克隆抗体(单抗)。选择在酶联免疫吸附检定(ELISA)及荧光激活细胞分选(FACS)检定中具有高结合活性的单抗以便进一步作表征。
用于免疫及结合检定的PD-1重组蛋白质
含有全长人类PD-1cDNA的表达质粒购自Origene(产品编号SC117011，NCBI登录号：NM_005018.1，中国，北京)。PCR扩增由PD-1的氨基酸(AA)1-168(序列编号1、序列编号2)组成的胞外域，在基于pcDNA3.1的表达载体(Invitrogen，Carlsbad，CA，USA)中亚克隆，其中C末端融合至His6标签或者融合至人类IgG4重链的γFc域，从而产生两个重组融合蛋白表达质粒PD-1-EC/His与PD-1-EC/Fc(缩写为PD-1/His与PD-1/Fc)。图1图示免疫原/抗原蛋白质的示意性呈现。针对重组融合蛋白产生，在1-3升培养基(Invitrogen)中将PD-1/His与PD-1/Fc质粒瞬时转染入293-F细胞，及在配备有旋转振动器的CO2培育箱中培养5-7天。收集含有重组蛋白质的上清液及在15000g下离心处理30分钟使该上清液透明。经由使用Ni-Sepharose Fast Flow(产品编号17531801，GE Lifesciences，中国，上海)的固定化金属亲和层析法，然后使用HiLoad 16/60Superdex 200柱(产品编号17106901，GE Lifesciences，中国，上海)执行大小排阻层析法纯化PD-1/His。使用蛋白G Sepharose Fast Flow柱(产品编号17061805，GE Lifesciences)纯化PD-1/Fc。用磷酸盐缓冲盐水(PBS)透析PD-1/His与PD-1/Fc蛋白质两者，并以小等分试样储存于-80℃冷冻箱中。
基于已公开序列(NCBI登录号：NM_014143)，藉由Genescript(中国，南京)化学合成编码人类PD-L1的cDNA。PD-L2表达质粒购自Origene(产品编号SC108873，NCBI登录号：NM_025239.2，中国，北京)。在pcDNA3.1/潮霉素(产品编号V870-20，Invitrogen)及pcDNA3.1/V5-His(产品编号V810-20，Invitrogen)中分别克隆两个cDNA。
稳定表达细胞系
藉由分别将含有PD-1、PD-L1及PD-L2的pcDNA3.1质粒转染至HuT78(ATCC，Manassas，VA，USA)及HEK293(ATCC)，及然后用含有每毫升200微克潮霉素(产品编号10687-010，Invitrogen)或1mg G418(Sigma)的培养基选择来建立表达人类PD-1、PD-L1或PD-L2的稳定细胞系。藉由常规方法分离单个克隆，该方法为有限稀释或从培养皿表面采集单个群落。分别使用抗PD-1、PD-L1及PD-L2抗体(产品编号12-9969、17-5983、12-5888，eBioscience，San Diego，USA)藉由Western印迹及FACS分析筛选所有克隆，及选择顶级表达克隆用于FACS结合检定以筛选杂交瘤单克隆抗体，或在功能性检定中使用。
免疫、杂交瘤融合及克隆
用含有5微克PD-1/Fc的100μl佐剂(产品编号KX0210041，康碧泉公司，中国，北京)皮下注射使八至十二周大Balb/c小鼠(购自北京华阜康生物科技股份有限公司，中国，北京)免疫。间隔三周注射上述免疫原两次来实施免疫。在第二次免疫后两周，藉由FACS(下文中)评估小鼠血清的PD-1结合。选择血清中具有高抗PD-1抗体滴度的小鼠及在腹膜内注射无任何佐剂的50微克PD-1/Fc进行强化。在强化后三天，使用标准技术(Gefter,M.L.等人，1977Somat Cell Genet，3:231-236)使脾细胞分离及与鼠类骨髓瘤细胞系SP2/0细胞(ATCC)融合。
藉由ELISA及FACS评估抗体的PD-1结合活性
如在“Flanagan,M.L.等人，2007Methods in Molecular Biology 378:33-52”中所描述的并略作修改，最初藉由酶联免疫吸附检定(ELISA)筛选杂交瘤克隆的上清液。简而言之，在96孔板(深圳市金灿华实业有限公司，中国，深圳)中的每个孔基底上包被50微升磷酸盐缓冲盐水(PBS)中50-200纳克PD-1/His或PD-1/Fc蛋白质。使用HRP偶联抗小鼠IgG抗体(产品编号7076S，Cell Signaling Technology，USA与中国上海)及化学发光试剂(产品编号PA107-01，TIANGEN，中国)检测及显现ELISA信号，该信号在450nm的波长处由读板仪(PHREAstar FS，BMG LABTECH，Germany)读取。使用常规方法藉由荧光激活细胞分选(FACS)进一步验证ELISA阳性抗体产生者克隆。在V形底96孔板(产品编号3897，Corning，USA与中国上海)中用来自抗PD-1杂交瘤的上清液染色上文所描述的PD-1稳定表达细胞系HuT78/PD-1(105个细胞/孔)。为了封闭人类Fc受体，用人类IgG(20μg/ml)(产品编号H11296，LifeHolder，USA与中国上海)预温育细胞。用DylightTM 649标记山羊抗小鼠IgG抗体(产品编号405312，Biolegend，Sandy Diego，USA)检测PD-1抗体及使用流式细胞仪(GuavaeasyCyte 8HT，Merck-Millipore，USA与中国上海)检测细胞荧光。
在ELISA与FACS检定两者中展示阳性信号的杂交瘤细胞的条件培养基经受功能性检定以鉴定在基于人类免疫细胞的检定中(在本文中)具有良好功能活性的抗体。进一步亚克隆及表征具有阳性功能活性的抗体。
亚克隆及对无血清或低血清培养基的适应
藉由受限稀释的常规方法亚克隆来自经由ELISA、FACS及功能性检定的初级筛选的阳性杂交瘤克隆。在96孔板中放入各个阳性克隆，在CO2培育箱中，在具有10％胎牛血清(FBS，产品编号SH30084.03，Hyclone，中国，北京)的RPMI1640培养基(产品编号SH30809.01B，Hyclone，中国，上海)中培养。选择各个有限稀释板中的三个亚克隆及藉由FACS及功能性检定表征这些亚克隆。将经由功能性检定所选择的亚克隆定义为单克隆抗体。顶级亚克隆经适应在具有1-3％FBS的CDM4MAb培养基(产品编号SH30801.02，Hyclone)中生长。
单克隆抗体的表达及纯化
在37℃的CO2培育箱中，在CDM4MAb培养基(产品编号SH30801.02，Hyclone)或Freestyle293表达培养基(产品编号12338018，Invitrogen)内分别培养产生鼠类单克隆抗体的杂交瘤细胞或重组抗体质粒转染的293-F细胞(产品编号R79007，Invitrogen)5至7天。经由在10,000g下离心处理30分钟移除所有细胞及细胞碎片收集条件培养基，并在纯化前经由0.22μm薄膜过滤。遵循制造商规则，将鼠类或重组抗体加入及结合至蛋白A柱(产品编号17127901，GE Life Sciences)，用PBS清洗，在含有20mM柠檬酸盐、150mM NaCl的缓冲液(pH3.5)中洗脱。用1M Tris pH8.0中和所洗脱物质，这些物质通常含有90％以上纯度的抗体。用PBS透析或使用HiLoad 16/60Superdex200柱(产品编号17531801，GE LifeSciences)进一步纯化经蛋白A亲和纯化的抗体以移除聚集体。藉由在280nm处测量吸收率或藉由Bradford检定(产品编号1856210，Thermo Scientific，Rockford，IL，USA)测定蛋白质浓度，使用所界定浓度的牛IgG(产品编号23212，Thermo Scientific)作为标准品。在-80℃的冷冻箱中以等分试样储存纯化抗体。
实施例2：抗PD-1抗体中的结合活性的比较
经由筛选数千种杂交瘤克隆，发明人鉴定出一些顶级单克隆抗体(单抗)，这些单克隆抗体以高特异性及强度结合人类PD-1。如ELISA检定(图2)所示，顶级抗体中的三者引发此结合强度及特异性。FACS分析结果表明，选定单克隆抗体结合至表达于细胞表面上的天然PD-1蛋白质。鼠类单抗317(mu317)、mu326及mu150展示出浓度依赖型结合活性，且其结合EC50(50％活性处的有效浓度)明显比对照mu55更低(图3)。
藉由表面等离子共振(SPR)评定单抗结合亲和力
对在ELISA及FACS中具有高结合活性以及在基于细胞的检定中(在本文中)具有有力功能活性的单抗在实时结合反应中检查结合动力学常数。使用蛋白A Flow柱(产品编号17531801，GE Life Sciences)，然后使用HiLoad 16/60Superdex200柱(产品编号17106901，GE Life Sciences)执行排阻层析法从杂交瘤上清液中纯化鼠类抗PD-1单抗。将纯化抗PD-1抗体浓缩至PBS中0.5-1mg/mL及以等份试样储存于-80℃冷冻箱中。
为了测定PD-1单抗的结合亲和力，使用BIAcoreTM T-200仪器(GE Life Sciences)在HBS-N缓冲液(10mM HEPES pH 7.4，0.15M NaCl，3mM EDTA，0.005％v/v表面活性剂P20，GE Healthcare)中执行SPR测量。使用标准伯胺偶联规程产生抗小鼠Fc CM5生物传感器芯片(GE Healthcare)。以10μl/分钟在抗小鼠Fc表面上捕捉0.3μg/ml的PD-1单抗达1分钟。以30μl/分钟在抗体结合表面上注射自3.3nM连续稀释至120nM的PD-1/Fc达3分钟，然后经历10分钟解离阶段。使用一对一朗谬(Langmuir)结合模型(BIA Evaluation Software,GELife Sciences)计算结合速率(Ka或kon)及解离速率(Kd或koff)。以比率koff/kon来计算平衡解离常数(KD)。
如表1所示，与mu317相关的关联序列家族成员mu326及mu517两者具有分别等于0.324nM及0.289nM的亚纳摩尔KD，此情况明显比mu134更佳。表1中所列出的三个单抗的kon速率相似，但koff速率明显不同，mu134中所观察到的解离速率快得多。
表1：某些顶级抗体的结合常数
藉由SPR测定抗PD-1Fab的亲和力
藉由PCR将抗PD-1单抗转换成Fab形式以使重链及轻链的可变区分别融合至人类IgG2-CH1及κ链恒定区的N末端，及在pcDNA3.1载体(Invitrogen)中亚克隆。使用与整个抗体的瞬时表达类似的瞬时转染方法在293-F细胞中共同表达两个表达载体。简而言之，PCR扩增Fabκ链及在基于pcDNA3.1的表达载体(Invitrogen，Carlsbad，CA，USA)中亚克隆。在另一质粒中，藉由交叠PCR将重链可变区(VH)以及来自人类IgG2中的CH1编码序列与C末端c-Myc-His8标签融合，及随后在表达载体中亚克隆。在IgG2重链中引入C232S及C233S(Kabat残基编号，Kabat等人，Sequence of proteins of immunologic interest，第5版，Bethesda,MD,NIH 1991)突变以防止二硫键交换及稳定人类IgG2处于IgG2-A构象(Lightle等人，2010Protein Sci 19(4):753-762)。两个构建体含有Fab成熟序列上游的信号肽。藉由上述2个质粒共同转染入293-F细胞实现Fab的分泌表达及在转染后6-7天收获细胞培养物上清液。使用Ni-Sepharose Fast Flow柱(产品编号17531801，GE Life Sciences)，然后使用HiLoad 16/60Superdex200柱(产品编号17106901，GE Life Sciences)执行大小排阻层析法从细胞培养物上清液中纯化带有His8标签的Fab。将纯化Fab浓缩至PBS中0.5-5mg/mL及以等份试样储存于-80℃冷冻箱中。
针对抗PD-1Fab的亲和力测定，使用BIAcoreTM T-200仪器(GE Life Sciences)进行SPR检定。简而言之，将人类PD-1/His或食蟹猴PD-1/His偶联至已活化的CM5生物传感器芯片(产品编号BR100530，GE Life Sciences)以实现大约100-200个响应单位(RU)，然后用1M乙醇胺封闭未反应基团。以30μL/分钟在SPR运行缓冲液(10mM HEPES,150mM NaCl,0.05％Tween20,pH7.4)中注射自0.12nM至90nM递增浓度的Fab样品，且藉由减去来自空白流动室的RU来计算人类PD-1/His或猴PD-1/His上的结合响应。使用一对一朗谬结合模型(BIA Evaluation Software,GE Life Sciences)计算结合速率(kon)及解离速率(koff)。以比率koff/kon来计算平衡解离常数(KD)。
表18中列出SPR测定的抗PD-1Fab的结合亲和力。各个抗PD-1Fab以高亲和力(KD＝0.15-1nM)结合至人类PD-1。除326-3G1外的所有Fab以略微较低但相当(KD的5倍内)亲和力结合至食蟹猴PD-1。
实施例3：抗PD-1抗体在人类T细胞中的功能活性
稳定细胞系的产生
逆转录病毒封装细胞系PT67、人类T细胞系HuT78及HEK293购自美国典型培养物保藏中心(ATCC,Rockville,MD)。根据前述操作程序(Zhang等人，2005Blood 106:1544-1551)，使用含有PD-1基因的pFB-neo载体(Strategene/Agilent Tech，Santa Clara，CA)藉由逆转录病毒转导产生表达PD-1的HuT78亚株HuT78/PD-1。藉由将抗人类CD3单抗OKT3的单链可变片段(scFv)(Kipriyanov等人，1997，PEDS 10:445-453)融合至小鼠CD8α的C末端域(113-220)(NCBI登录号：NP_001074579.1)建构T细胞接合物，膜锚定嵌合抗体(OS8)，该小鼠CD8α的C末端域包括铰链、跨膜及胞质域。藉由此举，将抗CD3 scFv锚定至细胞表面作为T细胞激活物。将人类PD-L1、PD-L2及OS8 cDNA亚克隆入pcDNA3.1载体。藉由用成对质粒共同转染HEK293及Hep3B细胞(ATCC)，然后用潮霉素或G418选择10-14天来产生共同表达OS8与PD-L1或PD-L2 cDNA两者的稳定细胞系HEK293/OS8/PD-L1、Hep3B/OS8/PD-L1及HEK293/OS8/PD-L2。随后藉由如先前所描述的有限稀释法克隆细胞系(Fuller SA等人，CurrProtoc Mol Biol.，第11章：第11.8.单元，2001)。藉由将人类PD-1的胞外域及跨膜域融合至人类CD3ζ链的胞质域(NCBI登录号：NP_932170.1)构建称为P3Z的嵌合PD-1受体。将P3Z编码cDNA序列克隆入pFB-neo，并经由逆转录病毒转导输送入HuT78细胞中以产生HuT78/P3Z细胞。
藉由HuT78/PD-1细胞中的IL-2释放测定PD-1抗体功能
为了测定抗PD-1抗体是否能阻断PD-L1诱导的PD-1信号传导的相互作用，用杂交瘤上清液或PD-1抗体预温育HuT78/PD-1细胞(在96孔板中每孔1.5x104个细胞)15分钟，之后在37℃下于平底板中与HEK293/OS8/PD-L1或HEK293/OS8/PD-L2细胞(每孔4x104)共同培养，每孔以200μl RPMI1640生长培养基供给营养。在16-18小时后，收集共同培养物上清液。藉由ELISA使用人类IL-2Ready-Set-Go！ELISA试剂盒(产品编号88-7025，eBiosciences，San Diego，CA)检定IL-2。在此检定中，用抗PD-1抗体阻断PD-1信号传导引发增强的TCR信号传导及IL-2产生(图4)。
如图5及表2所示，鼠类抗PD-1单抗mu317及mu326引发比mu30明显更高的功能活性，抑制PD-L1诱导的PD-1信号传导，从而导致IL-2分泌增加。两者比mu30抗体皆具有较高IL-2分泌(顶线，表2)，分别为675及634pg/ml，且两者皆具有更低的EC50(在IL-2分泌诱导的50％水平上的单抗的有效浓度)。
表2：与HEK293/OS8/PD-L1细胞共同培养的HuT78/PD-1细胞中藉由抗PD-1单抗所诱导的IL-2释放
由抗PD-1单抗结合HuT78/PD-1细胞不仅阻断了PD-L1诱导的T细胞激活，而且阻断了PD-L2诱导的IL-2释放。表3呈现数据，这些数据展示，mu317及mu326在激活T细胞中具有比mu476高得多的效能，如IL-2分泌的参数(EC50)所指示。
表3：与HEK293/OS8/PD-L2细胞共同培养的HuT78/PD-1细胞中藉由抗PD-1单抗所诱导的IL-2释放
藉由HuT78/P3Z细胞中的IL-2释放的反向信号传导测定PD-1抗体功能
在嵌合受体P3Z中，用CD3ζ的胞质域替换PD-1信号传导域。因此，P3Z在与PD-L1结合后介导激活，而非像原始PD-1受体那样产生抑制。在此检定中，用杂交瘤上清液或PD-1抗体预温育HuT78/P3Z细胞(3x104/孔)15分钟，之后在37℃于96孔平底板(总体积200μl/孔)中与HEK293/PD-L1或HEK293/PD-L2细胞(5x104/孔)共同培养。在16-18小时后，收集上清液及藉由如上所述的ELISA检定IL-2产生。
藉由在上文所描述的反向信号传导检定中直接读出T细胞激活进一步证实鼠类抗PD-1单抗的功能活性。与上文所描述的结果一致，mu317及mu326在发明人所筛选的单抗中具有最佳功能活性。如表4及表5所示，就IC50及最大抑制两方面而言，mu317及mu326比低活性单抗之一的mu37有力得多。
表4：在与HEK293/PD-L1细胞共同培养的HuT78/P3Z细胞中藉由抗PD-1单抗抑制IL-2分泌
表5：在与HEK293/PD-L2细胞共同培养的HuT78/P3Z细胞中藉由抗PD-1单抗抑制IL-2分泌
实施例4：与HEK293/OS8/PD-L1细胞共同培养的原代人类PBMC中藉由抗PD-1单抗激活IFN-γ分泌
为了验证针对PD-1选定的顶级单抗是否也对原代人类免疫细胞施加功能性效果，发明人藉由使用新鲜分离的外周血单个核细胞(PBMC)检定抗体功能，这些PBMC主要由T细胞(50-70％)、B细胞及NK细胞(15-30％)及单核细胞(2-10％)组成。根据制造商说明书，藉由使用Ficoll淋巴细胞分离介质(Histopaque-1077；Sigma-Aldrich，MO)的密度梯度离心处理而从健康供体中分离人类PBMC。所有人类血液采集遵循Beigene的内部程序。随后用抗CD3单抗(40ng/mL)OKT3(产品编号16-0037，eBioscience，CA)刺激PBMCs达3天，之后进行检定。FACS分析(实施例1)显示，激活的PBMC(原代T细胞)上的PD-1表达均有不同程度的增加，取决于不同供体(表6)。为了测定在结合TCR/CD3复合物后预激活T细胞对PD-1配体阳性肿瘤细胞的反应，在96孔平底板中将PBMCs(1x104)与HEK293/OS8/PD-L1或HEK293/OS8/PD-L2细胞(3x104)共同培养15-18小时。藉由ELISA使用Ready-Set-Go！ELISA试剂盒(产品编号88-7316，eBiosciences)对无细胞上清液检定IFN-γ水平，此IFN-γ水平为T细胞激活以及其他免疫细胞激活的最突出指标(Thakur A.等人，2012Vaccine，30:4907-4920)。
图6表明预激活PBMCs与HEK293/OS8/PD-L1细胞的共同培养液中存在单抗mu317及mu326导致以剂量依赖型方式增加IFN-γ累积。尽管用对照鼠类IgG处理的IFN-γ的基础水平在不同供体间各异，但由mu317或mu326处理的PBMC，在0.1至10μg/ml抗体处理范围内，IFN-γ分泌的增加在统计学上是明显的。与mIgG处理的PBMCs的对应水平相比，由介于0.1至10μg/ml浓度水平之间的mu317及mu326所诱导的IFN-γ分泌分别在供体-19的PBMCs中增加2.5至3.2倍及在供体-20的PBMCs中增加1.4至2.3倍。
实施例5：藉由抗PD1单抗激活人类NK细胞
用于NK细胞中的功能性检定的稳定细胞系
先前报告了原代人类NK细胞响应IL-2处理表达PD-1蛋白质及抑制PD-1介导的信号传导，增强了NK细胞的细胞毒性(2010Blood,116:2286)。为了定量检定NK细胞中由抗PD-1单抗所施加的功能效果，人类NK细胞系NK92MI(ATCC)及肺癌细胞系SK-Mes-1(ATCC)经工程设计以根据先前所描述的操作程序，藉由逆转录病毒转导分别稳定表达人类PD-1及PD-L1(Zhang等人，2005，Blood 106:1544-1551；Zhang等人，2006，Cancer Res，66:5927)。两个稳定细胞系被命名为NK92MI/PD-1及SK-Mes-1/PD-L1。
抗PD-1抗体促进NK92MI/PD-1细胞中的IFN-γ产生及分泌
藉由定量测量NK92MI/PD-1细胞中的IFN-γ产生及分泌检定抗PD-1单抗对NK细胞的功能活性，在96孔平底板中将这些NK92MI/PD-1细胞与肺癌细胞系SK-MES-1/PD-L1以1:2的比率共同培养，每孔总计6x104个细胞。在共同培养开始前15分钟，将抗PD-1单抗添加至NK92MI/PD-1细胞，随后在CO2培育箱中将这些细胞共同培养过夜。藉由实施例4中所描述的ELISA对无细胞上清液检定IFN-γ水平。
所有抗PD-1单抗触发IFN-γ产生，自具有低浓度抗体处理的基线明显增加至具有高浓度抗体处理的顶线。两个顶级抗体mu317及mu326具有比参照抗体5C更低的EC50，显示这些抗体具有对NK细胞有力得多的激活效果(表7)。
表7：在抗PD-1单抗及SK-MES-1/PD-L1细胞存在下，NK92MI/PD-1细胞在培养基中分泌的IFN-γ(pg/ml)
抗PD-1抗体增强由NK92MI/PD-1细胞所介导的癌细胞杀死
藉由使用CytoTox 96非放射性细胞毒性检定试剂盒(Promega，Madison，WI)的乳酸脱氢酶(LDH)释放检定测定NK92MI/PD-1细胞针对SK-MES-1/PD-L1细胞的细胞毒性。简言之，用抗PD-1单抗以最终浓度为0.004-10μg/ml的范围将NK92MI/PD-1细胞(105)预温育15分钟，并以效应细胞与肿瘤细胞(E:T)成5:1的比率将SK-MES-1/PD-L1细胞(2x104)添加至96孔V形底板中的免疫细胞培养物中，随后共同培养5小时。将完全肿瘤细胞裂解设定为最大细胞杀死，将各个样品的LDH释放检定读值计算为最大细胞杀死的百分比。使用基线的10％作为共同标准，跨板标准化所有样品的细胞杀死(％)。
在上文所设定的特异性细胞毒性检定中，所选定抗PD-1单抗以高浓度的单抗输入引发净肿瘤细胞杀死(＝顶线-基线)，范围自19％至20.2％。Mu317及mu326具有比mu336更低的EC50，显示触发NK92MI/PD-1细胞介导的肿瘤细胞杀死的较佳效力(表8)。
表8：由抗PD-1单抗诱导的NK92MI/PD-1细胞对肿瘤细胞的细胞毒性
实施例6：PD-1单抗的克隆及序列分析
在100mm组织培养皿中将分泌特定单抗的鼠类杂交瘤克隆培养至3x106至10x106个细胞的密度，经由在摇摆桶旋转器中以1500rpm离心处理来收获细胞。遵循制造商操作程序，使用Ultrapure RNA试剂盒(产品编号CW0581，CWBIOTECH，中国，北京)分离总细胞RNA。在二次去离子水中再悬浮RNA，藉由NanoDrop(ThermoFisher，中国，上海)测量浓度。
基于先前所报告的序列(Brocks等人，2001Mol Med 7:461-469)，藉由Invitrogen(中国，北京)合成用于单抗cDNA克隆的PCR引物。使用逆转录酶(产品编号AH301-02，Transgen Biotech，中国，北京)合成第一链cDNA。使用PCR试剂盒(产品编号Ap221-12，Transgen Biotech，中国，北京)且遵循制造商操作程序进行特定单抗cDNA的PCR扩增。由服务提供商对PCR产物直接测序(GeneWiz，中国，北京)或将PCR产物亚克隆入pCR载体(Invitrogen)，随后测序(GeneWiz)。
藉由序列同源性比对分析鼠类单抗的蛋白质序列。基于序列同源性及表位定位结果(实施例13)将单抗分组。基于Kabat(Wu,T.T.及Kabat,E.A.,1970J.Exp.Med.132:211-250)及IMGT系统(Lefranc M.-P.等人，1999Nucleic Acids Research，27，209-212)，藉由序列批注及藉由基于因特网的序列分析(http://www.imgt.org/IMGT_vquest/share/textes/index.html与http://www.ncbi.nlm.nih.gov/igblast/)鉴定互补决定区(CDR)。如表9所示，mu317及mu326的CDR在序列长度及同源性上极为不同。
表9：mu317及mu326的CDR
实施例7：鼠类单抗的人源化
抗体3D结构的模拟
针对mu317及mu326的可变域模拟三维结构，以便鉴定对于支持CDR环结构可能重要的框架残基。在第一轮抗体人源化中将潜在重要的框架残基保持为原始鼠类残基。采用先前建立的针对抗体的结构建模方法(Morea等人，Methods 2000 20:267-279)基于抗体的已知规范结构模拟抗PD-1单抗的3D结构(Al-Lazikani等人，1997Journal of MolecularBiology 273:927-948)。简而言之，在PDB数据库(Protein Data Bank，http://blast.ncbi.nlm.nih.gov/)中检索(blast)鼠类抗体的各个可变域(Vk及Vh)的序列以鉴定具有已知高分辨率结构(分辨率小于2.5埃)的最同源抗体序列。针对mu317及mu326建模选定的结构模板(表10中列出)在L-CDR1、L-CDR2、L-CDR3、H-CDR1及H-CDR2中具有与待建模的靶抗体相同类别的规范环结构。若Vκ及Vh的模板来自不同的免疫球蛋白，则藉由主链原子的最小平方拟合将这些模板堆叠(pack)在一起，以形成Vκ-Vh界面残基的杂合结构，该结构被Swiss模型程序用作结构同源性建模的模板(Kiefer等人，2009Nucleic Acids Research37，D387-D392)。在保持主链构象的同时，调整某些侧链构象。在亲本结构与建模结构具有相同残基的位点处，保持侧链构象。在残基为不同的位点处，在模板结构、旋转异构体库及堆叠考虑的基础上对侧链构象建模。在同源性建模后，使用PLOP程序(Jacobson等人，2002Journal of Physical Chemistry 106:11673-11680)细化同源性模型以最小化所有原子能量及优化Vκ及Vh界面。执行此步骤以改良立体化学，尤其是在来自不同抗体的结构的区段已被结合在一起的那些区域中。
表10：用于抗体结构模拟的结构模板
也针对CDR嫁接317-1及326-1模拟结构，以便导引更多轮抗体工程设计以增强人源化的程度及/或增强抗体稳定性。表10也列出选定结构模板。以与上文程序类似的方式实行结构模拟，所不同的是分别从针对317-1的PDB模板1AY1及针对326-1的模板3CXD中取得H-CDR3的可能构象，这些模板含有相似大小及躯干(torso)区域的H-CDR3。使用PLOP实行嫁接H-CDR3残基的能量最小化。
人源化
对于抗PD-1单抗的人源化，发明人藉由检索IMGT(http://www.imgt.org/IMGT_vquest/share/textes/index.html)及NCBI(http://www.ncbi.nlm.nih.gov/igblast/)网站中的人类免疫球蛋白基因数据库搜寻与mu317及mu326可变区的cDNA序列同源的人类种系IgG基因。将与PD-1单抗具有高同源性的人类IGVH及IGVκ选为人源化模板。
原则上藉由CDR嫁接实施人源化。在第一轮人源化中，如上文所描述的，藉由模拟3D结构导引可变区的框架序列中鼠类至人类氨基酸残基的突变，且仅使得其变化保持了总体抗体及CDR环结构的鼠类氨基酸残基突变至人类序列。人源化单抗的初始型式为hu317-1(序列编号47-50)及hu326-1(序列编号55-58)，它们包含：重链，其中人源化可变重链(Vh)融合至人类IgG2恒定区(NCBI登录号：P01859)；及轻链，其中人源化可变轻链κ(Vκ)融合至人类IgκC区(NCBI登录号：P01834)。同样地，发明人从mu317及mu326中产生嵌合抗体，这些嵌合抗体由融合至人类IgG2恒定区的鼠类VH及融合至人类IgκC区的鼠类Vκ组成。将全嵌合抗体分别命名为ch317及ch326。如实施例1所描述表达及纯化所有重组单抗。
FACS及功能性检定表明，单抗hu317-1几乎保持了与mu317及ch317相同的结合及功能活性。可藉由在FACS中使用两个不同检测抗体(山羊抗小鼠IgG及山羊抗人类IgG)的事实解读mu317对比ch317与hu317-1之间在FACS分析中的EC50差异。在两个功能性检定中，更同等地处理317的所有三个型式，且结果也接近于彼此(表11)。
作为针对mu326的初轮人源化的结果，单抗hu326-1保持了与亲本ch326及mu326相似的功能特征，尽管FACS结合检定及基于HuT78/PD-1细胞的IL-2释放检定中的功能活性可比ch326略微更弱(表12)。
表11：藉由FACS及功能性检定比较mu317、ch317及hu317-1
表12：藉由FACS及功能性检定比较mu326、ch326及hu326-1
/>
基于第一轮人源化，发明人进一步使hu317-1_Vh及_Vκ的框架(FR)中的其他鼠类氨基酸(AA)残基个别突变，以评估对抗体功能的影响。如表13所示，hu317-1的Vh中的七个个体突变及Vκ中的一个突变皆具有相似功能活性。在一些Vh突变中仅观察到较小变化，诸如hu317-2_K71V在突变中具有略微较弱的抑制功能。然而，当所有鼠类氨基酸残基一起突变成人类时(hu317-3A)，在FACS及IL-2释放检定中功能比其余突变明显更弱。
在上文所描述的初期试验中，除留下少数鼠类AA残基外，hu326-1在FR中达到明显的人源化水平。然而，hu326-1具有比mu326更弱的功能。因此，发明人实行更个别的突变，这些突变返回到鼠类残基或者朝向人类残基，以探索各个个体AA对单抗326功能的贡献。表14呈现基于hu326-1_Vh模板(序列编号56、序列编号57)产生的所有单个AA突变及其功能性检定结果。大多数突变展示出比hu326-1更好的功能活性，匹配原始mu326单抗。一对突变(E46K及F95Y)展示出EC50或IC50上略微较少的效力，表明那些残基在抗体结构及功能中的作用。
表13：hu317-1框架中具有人源化突变的Fab的功能活性的比较
/>
表14：hu326-1框架中具有突变的单抗的功能活性的比较
/>
为了探索可在人类中用作治疗剂的单抗317及326的最佳可能Vh及Vκ序列组成，发明人考虑到抗体特征实行各种组合突变(包括在CDR序列中的一些突变)，这些抗体特征诸如FR中的人源化水平、功能活性、物理化学特性、抗体依赖性细胞介导的细胞毒性(ADCC)及补体依赖性细胞毒性(CDC)。认为突变中的大多数未通过合格标准。经由工程设计过程，出于它们的潜在治疗效用选择人源化重组单抗中的六个：hu317-4B2(序列编号43-44)、hu317-4B5(序列编号45-46)、hu317-4B6(序列编号23-26)、hu326-3B1(序列编号51-52)、hu326-3G1(序列编号53-54)及hu326-4A3(序列编号27-30)。将单抗的CDRs与原始鼠类抗体相比较，展示于表15及表16中。
在六个单抗中，hu317-4B2、hu317-4B5及hu317-4B6在序列上彼此密切相关且在功能活性及强度上极为相似。另一方面，hu326-3B1、hu326-3G1及hu326-4A3在序列及功能性上彼此相当接近(表17-18)。在两组单抗的各者内，尽管存在一些较小差异，但它们也共享在序列及功能以外的许多其他特征，诸如物理化学特性及结合表位(实施例10及11中所描述)。
表15：单抗317的不同型式间的CDR比较
/>
表16：单抗326的不同型式间的CDR比较
/>
表17：藉由EL I SA及FAC S检定的人源化单抗的结合活性
表18：藉由SPR检定的Fab的结合亲和力
/>
藉由SPR的人源化抗PD-1Fab的亲和力测定
藉由PCR将抗PD-1单抗转换成Fab型式以使重链及轻链的可变区分别融合至人类IgG2-CH1及κ链恒定区的N末端，及在pcDNA3.1载体(Invitrogen)中亚克隆。使用与整个抗体的瞬时表达类似的瞬时转染方法在293-F细胞中共同表达两个表达载体。简而言之，PCR扩增Fabκ链及在基于pcDNA3.1的表达载体(Invitrogen，Carlsbad，CA，USA)中亚克隆。在另一质粒中，藉由交叠PCR将重链可变区(VH)以及来自人类IgG2中的CH1编码序列与C末端c-Myc-His8标签融合，及随后在表达载体中次克隆。在IgG2重链中引入C232S及C233S(Kabat残基编号，Kabat等人，Sequence of proteins of immunologic interest，第5版，Bethesda,MD,NIH 1991)突变以防止二硫键交换及稳定人类IgG2处于IgG2-A构象(Lightle等人，2010Protein Sci 19(4):753-762)。两个构建体含有Fab成熟序列上游的信号肽。藉由上述2个质粒共同转染入293-F细胞实现Fab的分泌表达及在转染后6-7天收获细胞培养物上清液。使用Ni-Sepharose Fast Flow柱(产品编号17531801，GE Life Sciences)，然后使用HiLoad 16/60Superdex200柱(产品编号17106901，GE Life Sciences)执行大小排阻层析法从细胞培养物上清液中纯化带His8标签的Fab。将纯化Fab浓缩至PBS中0.5-5mg/mL及以等份试样储存于-80℃冷冻箱中。
为了抗PD-1Fab的亲和力测定，使用BIAcoreTM T-200仪器(GE Life Sciences)进行SPR检定。简而言之，将人类PD-1/His或食蟹猴PD-1/His偶联至已活化的CM5生物传感器芯片(产品编号BR100530，GE Life Sciences)以实现大约100-200个响应单位(RU)，然后用1M乙醇胺封闭未反应基团。以30μL/分钟在SPR运行缓冲液(10mM HEPES,150mM NaCl,0.05％Tween20,pH7.4)中注射自0.12nM至90nM递增浓度的Fab样品，且藉由减去来自空白流动室的RU来计算在人类PD-1/His或猴PD-1/His上的结合响应。使用一对一朗谬结合模型(BIA Evaluation Software,GE Life Sciences)计算结合速率(kon)及解离速率(koff)。以比率koff/kon来计算平衡解离常数(KD)。
表18中列出SPR测定的抗PD-1Fab的结合亲和力。各个抗PD-1Fab以高亲和力(KD＝0.15-1nM)结合至人类PD-1。除326-3G1外的所有Fab以略微较低但相当(KD的5倍内)亲和力结合至食蟹猴PD-1。
实施例8：具有经修饰人类IgG4恒定区的重组抗PD-1单抗的产生及表达
由于PD-1主要表达于激活T细胞中，连接至天然产生类型IgG-Fc模块的PD-1阻断性抗体预期取决于IgG亚类会以不同程度诱导Fc介导的效应器功能(诸如ADCC及CDC)，从而导致消除激活T细胞(Natsume A等人，2009Drug Des Devel Ther.3:7-16)。在许多先前报告中已展示人类抗体亚类IgG4，IgG4具有适度ADCC且几乎没有CDC效应器功能(Moore GL等人，2010MAbs，2:181-189)。另一方面，已发现天然IgG4在压力条件下(诸如在酸性缓冲液中或在上升的温度下)不太稳定(Angal,S.1993Mol Immunol，30:105-108；Dall'Acqua,W.等人，1998Biochemistry，37:9266-9273；Aalberse等人，2002Immunol，105:9-19)。为了使PD-1+T细胞免遭杀死及改良抗PD-1抗体的物理化学特性，将人源化单抗连接至由突变组合所设计的IgG4以具有减小的或零FcγR结合或C1q结合活性，因此减弱或消除ADCC及CDC效应器功能。考虑到抗体作为生物学药物的物理化学特性，IgG4的不太理想的固有特性之一为其在溶液中动态分离两个重链而形成半抗体，此举导致经由称为“Fab臂交换”的过程在体内产生双特异性抗体(Van der Neut Kolfschoten M等人，2007Science，317:1554-157)。在位置228(EU编号系统)处的丝氨酸至脯氨酸的突变呈现对IgG4重链分离的抑制(Angal,S.1993Mol Immunol，30:105-108；Aalberse等人，2002Immunol，105:9-19)。已报告铰链及γFc区中的一些氨基酸残基对抗体与Fcγ受体的相互作用具有影响(Chappel SM等人，1991Proc.Natl.Acad.Sci.USA，88:9036-9040；Mukherjee,J.等人，1995FASEB J，9:115-119；Armour,K.L.等人，1999Eur J Immunol，29:2613-2624；Clynes,R.A.等人，2000NatureMedicine，6:443-446；Arnold J.N.，2007Annu Rev Immunol，25:21-50)。此外，人类群体中一些罕见发生的IgG4同等型也可引发不同的物理化学特性(Brusco,A.等人，1998Eur JImmunogenet，25:349-55；Aalberse等人，2002Immunol，105:9-19)。然而，将先前发现的所有突变及同等型集中成特定抗体并不保证理想抗体分子共享诸如上文所描述的用作治疗剂的所有特征，原因可为组合突变的矛盾效果及可变区对抗体的效应器功能及物理化学特性的影响(Igawa T.等人，2010Prot Eng Design Select，23:385-392；Perchiacca J.M.与Tessier P.M.，2012Ann Rev Biomol Eng 3:263-286)。
为了产生具有最小ADCC、CDC及不稳定性的抗PD-1单抗，发明人藉由引入一定数目突变组合来修饰人类IgG4的铰链及γFc区，创建IgG4mt1至IgG4mt12。如发明人的检定结果所示，一些经修饰的IgG4变体显然不太理想，表19中列出若干相关IgG4变体及修饰后序列。本文描述这些抗体的评估。
表19：IgG4变体的序列修饰
/>
实施例9：IgG4mt10没有FcγR结合、具有最低的ADCC及CDC效应器功能
当抗体结合至细胞表面靶蛋白质，然后连接至效应细胞上所表达的Fcγ受体(FcγR)时，启动ADCC。很清楚地记载了人类IgG1对FcγR具有比IgG2及IgG4明显更高的结合亲和力，尤其是结合FcγR-I及FcγR-IIIA，该亲和力与IgG1激活ADCC的强度相关联。联想到ADCC，当抗体交联细胞表面靶点及C1q蛋白质，继之以补体复合物形成及靶细胞裂解的级联反应时，激活CDC。作为ADCC及CDC的代理，抗体结合至FcγR及C1q的检定可充当ADCC及CDC的基本指标。因此，发明人系统地评估单抗对所有主要FcγR的结合。
FcγR结合
藉由流式细胞术测定各种IgG4突变体对FcγR的结合。简言之，建立表达人类FcγR的一系列HEK293转染子。这些转染子表达FcγRI、FcγRIIA、FcγRIIB或FcγRIIIA。与FcRγ共同表达多亚基FcγR(即，FcγRI及FcγRIIIA)。还包括多态性变体(即，FcγRIIA H131与R131、FcγRIIIA F158与V158)。使用二体(山羊抗人类IgG F(ab)'2-Alexa Fluor 488，Jackson Immuno Research，West Grove，PA，USA)检测抗PD-1单抗与经修饰IgG4变体(表19)对FcγR+HEK293细胞的结合。如预期，IgG1型式的抗PD-1单抗(hu317-1/IgG1及hu317-4B6/IgG1)强有力地结合所有FcγR，包括FcγRI、FcγRIIA(H131及R131等位基因)、FcγRIIB及FcγRIIIA(V158及F158等位基因)(表20)。有趣的是，当以相同IgG4变体型式(诸如IgG4mt1或者IgG4mt6型式)产生两个不同型式的人源化单抗，即hu317-1及hu317-4B6(在Vh及Vκ两者中具有差异)时，它们的结合强度(MFI)自2倍至接近于100倍的范围变化(例如，455.2/115.7＝3.9倍；13.6/1.0＝13.6倍；434.6/4.9＝88.7倍；等等，参看表20)。与其他人的先前发现一致的是，抗体的可变区对与FcR的结合具有明显影响，因此，对诸如ADCC的效应器功能施加影响(Igawa T.等人，2010Prot Eng Design Select，23:385-392；Perchiacca J.M.与Tessier P.M.，2012Ann Rev Biomol Eng 3:263-286)。
如表20中所表明，当以IgG4mt10型式产生hu317-4B6及hu326-4A3时，它们在表中所列出的PD-1单抗及IgG变体型式中以及研究中已测试的许多其他人源化单抗及IgG型式中具有对FcγR的最低结合活性。IgG4mt10型式的hu317-4B6及hu326-4A3在这个方面的独特性不可延伸至具有某些远序列同源性的人源化单抗的相同家族(诸如hu317-1)，如上文所描述。
表20：由FACS所测定的抗PD-1单抗对FcγR的结合强度(MFI*)
ADCC
经典ADCC涉及藉由抗体结合至FcγRIIIA或CD16而激活NK细胞。为了验证人源化抗PD-1单抗是否诱导ADCC，将NK92MI/CD16V细胞用作效应细胞，该细胞藉由共同转导含有CD16(V158等位基因)与FcRγ基因的表达质粒自NK92MI细胞(ATCC)产生，及将表达PD-1的T细胞系HuT78/PD-1用作靶细胞。在96孔V形底板中将NK92MI/CD16V细胞(4x104)与相等数目的HuT78/PD-1细胞共同培养5小时。由前文中所描述的LDH释放检定测定细胞毒性。结果确认，与阳性对照相比较，hu317-4B2/IgG4mt6、hu317-4B6/IgG4mt6、hu317-4B6/IgG4mt10及hu326-4A3/IgG4mt10全部具有ADCC的基础水平(图7)。那4个单抗之间ADCC的较小差异可归因于实验误差(参看图7中的误差棒)。
CDC
大体而言，人类IgG4抗体并不经由经典路径诱导任何CDC。使用PD-1表达T细胞系HuT78/PD-1及来自健康供体的新鲜人类血清评估IgG4mt10型式的抗PD-1单抗是否会触发CDC。藉由Celltiter glo检定试剂盒(Promega，中国，北京)测定CDC的细胞裂解。简言之，在96孔平底板中，在37℃在具有抗PD-1抗体(10μg/ml)的无血清RPMI1640(Invitrogen)中温育HuT78/PD-1细胞(2x104)15分钟，随后添加正常人类血清(NHS)，终浓度为15％或50％，总体积为120μl。在37℃过夜温育后，细胞裂解并检定ATP浓度。为了测试IgG4mt10的人源化抗PD-1单抗是否能经由CDC杀死PD-1+原代T细胞，用抗CD3抗体OKT3(40ng/ml)预激活自健康供体分离的PBMCs达3天，随后与抗PD-1抗体加NHS共同培养。ATP量与培养液中存在的细胞数目成正比。使用96孔荧光计(PHERA Star FS,BMG LABTECH)读取荧光。以与活细胞数目成比例的相对荧光单位(RFU)表述这些结果。百分比CDC活性计算如下：％CDC活性＝[(RFU测试-RFU背景)/(完全细胞裂解下的RFU-背景下的RFU)]x100。大体而言，发明人未能检测由结合至激活PBMCs的IgG4mt10型式的抗PD-1单抗所介导的任何ADCC。在高度敏感性实验条件下，诸如使用PD-1高表达细胞系、高血清与抗体浓度，发明人在一些场合中检测到极低水平的CDC，且不同型式与抗PD-1单抗之间不存在太多差异，此指示IgG4变体型式的抗PD-1单抗保持与常见形式的IgG4相同的低CDC活性或无CDC活性的特征。
实施例10：IgG4mt10型式的人源化抗PD-1单抗在压力条件下具有增强的稳定性
抗PD-1抗体在高温及酸性条件中的稳定性
用于稳定性研究的抗PD-1抗体全部由前文中所描述的蛋白A柱及随后的大小排阻层析法(SEC)纯化。在纯化后，在分析性大小排阻层析法-高效液体层析法(SEC-HPLC)中监测纯化抗体样品的聚集体含量，这些含量处于0％-0.5％的范围内。
对于SEC-HPLC分析，在等度洗脱条件下(洗脱缓冲液0.2M磷酸钠，pH7.2)，使用TSKgel G3000 SWXL柱(7.8x300 mm，产品编号08541，Tosoh Bioscience，中国，上海)分析抗体样品，随后在UV-215nm处检测。在各次执行中，将10微升抗体样品加载到柱上并以1mL/分钟的流速洗脱。将抗体的二聚体或较大聚集体种类与单体种类分开，并基于UV线的积分峰面积测定二聚体及聚集体的百分比。
对于速度增强的贮存稳定性研究，将抗PD-1抗体(PBS中10-40mg/mL)保存于40-50℃的培育箱中长达4-7天，以便测试抗体在高温条件中的稳定性。随后在SEC-HPLC中针对热诱导形成二聚体及聚集体分析抗体样品。对于所分析的各个抗PD-1抗体，2％以下变成较高分子量种类(二聚体及聚集体)，说明抗PD-1抗体在高温条件下具有良好稳定性。
在下游制造过程中，酸性条件中的抗体稳定性已成为关键性挑战(Liu等人，2010mAbs 2:480-499)。自蛋白A的抗体洗脱及病毒的灭活通常需要在低pH(2.5-4)条件中温育抗体。然而，此类酸性条件可潜在引发抗体变性及聚集。已知人类IgG4比IgG1及IgG2稳定性低(2002Immunology 105:9)。因此，发明人检定用各种IgG4突变体型式所产生的人源化单抗。简而言之，藉由1:1体积的各个抗体样品(PBS中10mg/mL)与低pH缓冲液混合研究低pH条件中的抗体稳定性，这些缓冲液含有50mM柠檬酸钠，100mM NaCl，pH分别为3.6、3.3、3.0或2.7。在室温下温育1小时后，藉由1:5稀释入含有0.2M磷酸钠(pH7.2)的SEC-HPLC洗脱缓冲液中和低pH条件中的抗体样品。如上文所描述进行SEC-HPLC分析及量化由低pH条件所诱导的二聚体及聚集体的百分比。IgG1型式的抗PD-1单抗317-4B6在生物工艺相关的酸性条件中最稳定，即使当pH值低到2.7时亦如此。在若干IgG4变体中产生的抗PD-1单抗之中，hu317-4B6/IgG4mt10与hu326-4A3/IgG4mt10在酸性缓冲液条件下最稳定(表21)，因为酸诱导的聚集体明显减少到与IgG1型式的抗PD-1单抗317-4B6及326-4A3相当的水平(即，可溶性聚集体小于2％(表21))。
表21：在酸性缓冲液中形成及藉由SEC-HPLC检定的二聚体及可溶性聚集体
实施例11：定位抗PD-1单抗的结合表位
关于PD-1/PD-L1及PD-1/PD-L2复合物的晶体结构的先前报告已经阐明而理解PD-1上配体结合所需要的关键氨基酸(AA)残基(Zhang等人，2004Immunity，20:337-347；LinD.Y.等人，2008PNAS 105:3011-3016；Lazar-Molnar E.等人，2008PNAS，105:10483-10488)。事实上，在受体上经由点突变分析鉴定此类AA残基中的六个是PD-L1结合所需要的。六个AA残基中的五个也是PD-L2结合所需要的(Lin D.Y.等人，2008PNAS 105:3011-3016)。基于结构导引突变分析中的信息，发明人假设，功能性单抗阻断PD-1介导的信号传导的最有效方式为藉由结合至六个关键AA残基，从而占据配体结合所需要的结合表位而与PD-1配体竞争。为了探索该假设及理解功能性PD-1抗体的作用机制，发明人已藉由将六个关键AA的每一个个别地替换成Ala，产生PD-1的六个突变体，即K45A、I93A、L95A、P97A、I101A及E103A(基于Lin D.Y.等人，2008PNAS 105:3011-3016进行的AA残基编号)。将突变型PD-1/Fc及PD-1/His(图1)作为模板，用于使用快速诱变系统(产品编号FM111，TransgenBiotech，中国，北京)的PCR导引诱变或滚环诱变。在发明人基于pcDNA的表达载体中亚克隆所有突变体，并藉由测序验证。藉由瞬时转染(实施例1中所描述)表达突变型及野生型PD-1蛋白质，并在培养4-6天后制备这些蛋白质。藉由Western印迹分析条件培养基(CM)，以就质量与数量而言验证PD-1蛋白质表达。在清除细胞碎片后，在ELISA分析或Western印迹中直接使用上清液(CM)以进行表位定位。
为了研究人源化抗PD-1单抗的结合表位，执行使用野生型(WT)及突变型(Mt)PD-1的ELISA检定以评估hu317-4B5、hu317-4B6、hu326-3B1及hu326-4A3的结合活性。为了进行比较以检查抗体结合签名的独特性，在研究中包括两个参考抗体(分别来自US8008449B2及US8168757B2的参考抗体-1与参考抗体-2)。在相同ELISA检定中，在用于所有单抗的96孔板中包被相等体积的含有WT或Mt PD-1的CM。使用WT PD-1结合信号的平均ELISA读数作为标准，标准化所有ELISA结果。针对对某特定Mt PD-1的最高抗体结合读数(设定为100％)进一步标准化针对该特定Mt PD-1的ELISA结合信号。为了便于数据分析，当单抗针对特定突变体的ELISA结合信号相对于WT PD-1下降到50％以下时，将该氨基酸残基定义为明显结合表位，因为其突变明显消除了抗体结合。同样地，若单抗针对特定突变体的ELISA结合信号下降到25％以下，则定义为极其明显。如图8所示，PD-1中关键AA残基中的两者K45及I93为单抗hu317-4B5及hu317-4B6结合的明显或极其明显表位，且三个AA残基I93、L95及P97为hu326-3B1及hu326-4A3的明显或极其明显表位。另一方面，两个参考抗体具有可区别的结合表位，P97对于参考抗体-1明显，而L95及P97对于参考抗体-2明显。
有趣的是，当PD-1蛋白质在Western印迹中变性后，单抗hu317-4B5及hu317-4B6仍然能够结合至WT PD-1，虽然关键结合表位(K45及I93)彼此并不接近(非线性)。此表明，在Western印迹过程的SDS-PAGE中变性后，PD-1蛋白质在某种程度上复性，从而允许抗PD-1单抗识别及结合它。利用此观察结果，发明人针对上文ELISA研究中所使用的所有六个抗体执行Western印迹分析。Western印迹的总体结果很好地印证了ELISA结果，即，，其突变在ELISA中引发弱结合信号的明显或极其明显表位也提供与其他突变型PD-1的结合相比最弱的Western印迹带(图8)。还观察到ELISA与Western印迹之间的一些较小差异，例如，由参考抗体-2在I93A及E103A上的ELISA结合信号比Western印迹中的信号相对更强。这可能指示，那些AA残基还可帮助结合，因为那些AA残基突变影响结合，但仅在压力条件下(即，变性或丧失天然构象)。如表22中所归纳的，本发明中的抗PD-1单抗具有与其他抗PD-1抗体不同的可鉴定结合表位。
表22：抗PD-1单抗的关键表位的归纳*
实施例12：抗PD-1单抗在异种移植物小鼠模型中激活原代人类PBMC及抑制肿瘤生长
人源化抗PD-1单抗激活人类PBMC
贯穿人源化过程，人源化抗PD-1单抗在各种阶段处保持相似功能活性，由ELISA、FACS及基于免疫细胞的细胞因子释放检定评估该功能活性。为了确认人源化单抗的最终型式的功能，发明人使用原代人类PBMCs检定了hu317-4B5、hu317-4B6、hu326-3B1及hu326-4A3的激活功能。结果表明，尽管因个体遗传背景不同造成四个供体之间的激活程度不同，但贯穿人源化的那些单抗维持了原始鼠类单抗激活原代PBMC的功能(图9)。
人源化抗PD-1单抗增强基于NK细胞的对癌细胞的细胞毒性
联想到原始鼠类单抗，人源化抗PD-1单抗hu317-4B5、hu317-4B6、hu326-3B1及hu326-3G1以剂量依赖型方式增强针对靶肺癌细胞SK-MES-1/PD-L1的NK92MI/PD-1细胞介导的细胞毒性(图10，表23)。很明显，原理上人源化抗PD-1单抗可发挥破坏由PD-1信号传导所介导的免疫细胞耐受的功能，从而增强免疫细胞(例如，NK细胞及细胞毒性T淋巴细胞)的杀癌活性。
人源化抗PD-1单抗在小鼠异种移植物癌症模型中体内激活人类PBMCs及抑制肿瘤生长
所有上述实验证据显示，抗PD-1单抗可在小鼠癌症模型中起作用，这些模型利用异种移植有人类癌细胞的免疫受损小鼠，随后植入人类PBMCs及应用单抗处理，以抑制体内癌细胞生长。实验设计如下。在七至八周大SCID雄性小鼠(Vital River Laboratories，中国)右体侧处皮下接种50％Matrigel(BD Biosciences，New Jesey，USA)中的3x106个Hep3B/OS8-PD-L1细胞。在肿瘤接种后15天，使带肿瘤大小100-250mm3的小鼠随机分为三个处理组。瘤内注射来自2个健康供体的100微升汇集PBMCs(5x105)。在PBMCs植入后3天，经由皮下注射以10mg/kg的剂量分别施用抗PD-1抗体(Hu317-IgG4mt2)及人类IgG。抗体处理每10天重复一次，共计3次。在平行组中注射PBS作为阴性对照。在第7天开始，使用测径规每周两次测量肿瘤。使用以下公式计算肿瘤体积：[D x(d2)]/2，其中D表示肿瘤的大直径，及d表示小直径。所有动物研究皆遵循Beigene动物护理及使用程序执行。
在体内研究中，尽管对照组中的60％肿瘤为自动消退，但体内实验的剩余部分仍相当具有教益，此呈现于图11中。在对照组中，媒剂处理组或人类IgG(huIgG)处理组各具有40％的肿瘤(5只小鼠中的2只)比在起始点处的基线长出更大。PBS处理组中的两个肿瘤生长大得多(2000mm3以上，由于超过规程的肿瘤大小限制，提前终止一只带肿瘤小鼠)。huIgG处理组中的两个肿瘤生长到800及1370mm3的大小，明显超过164mm3的平均基线，但比PBS处理的肿瘤小。另一方面，在抗PD-1单抗(hu317-1/IgG4mt2)处理组中，肿瘤完全消退或者接近于基线大小(一个肿瘤＝200mm3，该肿瘤在自PBMC植入起两周时消退到基线的50％后缓慢重新生长)。结果显示，上文所描述的抗PD-1单抗能在小鼠体内癌症模型中激活抑制肿瘤细胞生长的人类免疫细胞，该结果与上文所描述的体外实验结果一致。
序列表
<110> 百济神州有限公司
李康
张彤
宋兢
徐兰兰
刘琦
彭浩
<120> 抗PD1抗体及其作为治疗剂与诊断剂的用途
<130> BGB 108
<160> 90
<170> PatentIn version 3.5
<210> 1
<211> 444
<212> DNA
<213> 人（Homo sapiens）
<400> 1
ccaggatggt tcttagactc cccagacagg ccctggaacc cccccacctt ctccccagcc 60
ctgctcgtgg tgaccgaagg ggacaacgcc accttcacct gcagcttctc caacacatcg 120
gagagcttcg tgctaaactg gtaccgcatg agccccagca accagacgga caagctggcc 180
gccttccccg aggaccgcag ccagcccggc caggactgcc gcttccgtgt cacacaactg 240
cccaacgggc gtgacttcca catgagcgtg gtcagggccc ggcgcaatga cagcggcacc 300
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagagag cctgcgggca 360
gagctcaggg tgacagagag aagggcagaa gtgcccacag cccaccccag cccctcaccc 420
aggccagccg gccagttcca aacc 444
<210> 2
<211> 148
<212> PRT
<213> 人（Homo sapiens）
<400> 2
Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr
1 5 10 15
Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe
20 25 30
Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr
35 40 45
Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu
50 55 60
Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu
65 70 75 80
Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn
85 90 95
Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala
100 105 110
Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg
115 120 125
Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly
130 135 140
Gln Phe Gln Thr
145
<210> 3
<211> 354
<212> DNA
<213> 小家鼠（Mus musculus）
<400> 3
caggtgcagc tgaaggagtc aggacctggc ctggtggcgc cctcaaagaa cctgtccatc 60
acttgcactg tctctgggtt ttcattaacc agctatggtg tacactggat tcgccagcct 120
ccaggaaagg gactggaatg gctgggagta atatgggccg gtggaagcac aaattataat 180
tcggctctca tgtccagact gagcatcagc aaagacaact ccaggagcca agttttctta 240
agaatgaaca gtctgcaaac tgatgacaca gccatgtact actgtgccag agcctatggt 300
aactactggt acatcgatgt ctggggcgca gggaccacgg tcaccgtctc ctca 354
<210> 4
<211> 118
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 4
Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Lys
1 5 10 15
Asn Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Arg Ser Gln Val Phe Leu
65 70 75 80
Arg Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Ala Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 5
<211> 321
<212> DNA
<213> 小家鼠（Mus musculus）
<400> 5
gacattgtga tgacccagac tcccaaattc ctgcttgtat cagcaggaga cagggttacc 60
ataacctgca aggccagtca gagtgtgagt aatgatgtag cttggtacca acagaagcca 120
gggcagtctc ctaaactgct gataaactat gcatttcatc gcttcactgg agtccctgat 180
cgtttcactg gcagtggata tgggacggat ttcattttca ccatcagcac tgtgcaggct 240
gaagacctgg cagtttattt ctgtcaccag gcttatagtt ctccgtacac gttcggaggg 300
gggaccaagc tggaaatgaa a 321
<210> 6
<211> 107
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 6
Asp Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Ile Phe Thr Ile Ser Thr Val Gln Ala
65 70 75 80
Glu Asp Leu Ala Val Tyr Phe Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105
<210> 7
<211> 342
<212> DNA
<213> 小家鼠（Mus musculus）
<400> 7
cagatccagt tggtgcagtc tggacctgag ctgaagaagc ctggagagac agtcaagatc 60
tcctgcaagg cttctgggta taccttcaca aactatggaa tgaactgggt gaagcaggct 120
ccaggaaagg gtttaaagtg gatgggctgg ataaacaata ataatggaga gccaacatat 180
gctgaagagt tcaagggacg gtttgccttc tctttggaaa cctctgccag cactgcctat 240
ttgcagatca acaacctcaa aaatgaggac acggctacat atttctgtgc aagagatgtt 300
atggactatt ggggtcaagg aacctcagtc accgtctcct ca 342
<210> 8
<211> 114
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 8
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Glu Glu Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val
100 105 110
Ser Ser
<210> 9
<211> 330
<212> DNA
<213> 小家鼠（Mus musculus）
<400> 9
gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 60
atatcctgca gagccagtga aagtgttgat aattatggct atagttttat gcactggtac 120
cagcagaaac caggacagcc accccaactc ctcatctatc gtgcatccaa cctagaatct 180
gggatccctg ccaggttcag tggcagtggg tctaggacag gcttcaccct caccattaat 240
cctgtggagg ctgatgatgt tgcaacctat tactgtcagc aaagtaaaga atatccgacg 300
ttcggtggag gcaccaagct ggaagtcaaa 330
<210> 10
<211> 110
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 10
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Gln Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Gly Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Val Lys
100 105 110
<210> 11
<211> 10
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 11
Gly Phe Ser Leu Thr Ser Tyr Gly Val His
1 5 10
<210> 12
<211> 16
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 12
Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met Ser
1 5 10 15
<210> 13
<211> 12
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 13
Ala Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val
1 5 10
<210> 14
<211> 11
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 14
Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala
1 5 10
<210> 15
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 15
Tyr Ala Phe His Arg Phe Thr
1 5
<210> 16
<211> 9
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 16
His Gln Ala Tyr Ser Ser Pro Tyr Thr
1 5
<210> 17
<211> 10
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 17
Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
1 5 10
<210> 18
<211> 17
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 18
Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys
1 5 10 15
Gly
<210> 19
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 19
Ala Arg Asp Val Met Asp Tyr
1 5
<210> 20
<211> 15
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 20
Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Tyr Ser Phe Met His
1 5 10 15
<210> 21
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 21
Arg Ala Ser Asn Leu Glu Ser
1 5
<210> 22
<211> 8
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 22
Gln Gln Ser Lys Glu Tyr Pro Thr
1 5
<210> 23
<211> 354
<212> DNA
<213> 人工序列
<220>
<223> 317-4B6 cDNA-Vh
<400> 23
caggtgcagc tgcaggagtc gggaccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggtt ttcattaacc agctatggtg tacactggat ccggcagccc 120
ccagggaagg gactggagtg gatcggggtc atatacgccg atggaagcac aaattataat 180
ccctccctca agagtcgagt gaccatatca aaagacacct ccaagaacca ggtttccctg 240
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agcctatggt 300
aactactggt acatcgatgt ctggggccaa gggaccacgg tcaccgtctc ctca 354
<210> 24
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B6 pro-Vh
<400> 24
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Tyr Ala Asp Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 25
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 317-4B6 cDNA-Vk
<400> 25
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcga gagtgtgagt aatgatgtag cttggtacca gcagaaacca 120
ggacagcctc ctaagctgct cattaactat gcatttcatc gcttcactgg ggtccctgac 180
cgattcagtg gcagcgggta tgggacagat ttcactctca ccatcagcag cctgcaggct 240
gaagatgtgg cagtttatta ctgtcaccag gcttatagtt ctccgtacac gtttggccag 300
gggaccaagc tggagatcaa a 321
<210> 26
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 317-4B6 pro-Vk
<400> 26
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Glu Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 27
<211> 342
<212> DNA
<213> 人工序列
<220>
<223> 326-4A3 cDNA-Vh
<400> 27
caggtgcagc tggtgcagag cggcagcgag ctgaagaagc ccggcgccag cgtgaaggtg 60
agctgcaagg ccagcggcta caccttcacc aactacggca tgaactgggt gagacaggcc 120
cccggccagg gcctgaagtg gatgggctgg atcaacaaca acaacgccga gcccacctac 180
gcccaggact tcagaggcag attcgtgttc agcctggaca ccagcgccag caccgcctac 240
ctgcagatca gcagcctgaa gaccgaggac accgccgtgt actactgcgc cagagacgtg 300
atggactact ggggccaggg caccctggtg accgtgagca gc 342
<210> 28
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-4A3 pro-Vh
<400> 28
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Ala Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 29
<211> 330
<212> DNA
<213> 人工序列
<220>
<223> 326-4A3 cDNA-Vk
<400> 29
gacattgtgc tgacccagtc tccagcctcc ttggccgtgt ctccaggaca gagggccacc 60
atcacctgca gagccagtga aagtgttgat aattatggct atagttttat gcactggtat 120
cagcagaaac caggacaacc tcctaaactc ctgatttacc gtgcatccaa cctagaatct 180
ggggtcccag ccaggttcag cggcagtggg tctgggaccg atttcaccct cacaattaat 240
cctgtggaag ctgaggatac tgcaaattat tactgtcagc aaagtaaaga atatccgacg 300
ttcggcggag ggaccaaggt ggagatcaaa 330
<210> 30
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-4A3 pro-Vk
<400> 30
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Glu Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 31
<211> 10
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 31
Gly Phe Ser Leu Thr Ser Tyr Gly Val His
1 5 10
<210> 32
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 317-4B6 H-CDR2 或 CDR-H2
<400> 32
Val Ile Tyr Ala Asp Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 33
<211> 12
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 33
Ala Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val
1 5 10
<210> 34
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 317-4B6 L-CDR1 或 CDR-L1
<400> 34
Lys Ser Ser Glu Ser Val Ser Asn Asp Val Ala
1 5 10
<210> 35
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 35
Tyr Ala Phe His Arg Phe Thr
1 5
<210> 36
<211> 9
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 36
His Gln Ala Tyr Ser Ser Pro Tyr Thr
1 5
<210> 37
<211> 10
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 37
Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
1 5 10
<210> 38
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 326-4A3 H-CDR2 或 CDR-H2
<400> 38
Trp Ile Asn Asn Asn Asn Ala Glu Pro Thr Tyr Ala Gln Asp Phe Arg
1 5 10 15
Gly
<210> 39
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 39
Ala Arg Asp Val Met Asp Tyr
1 5
<210> 40
<211> 15
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 40
Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Tyr Ser Phe Met His
1 5 10 15
<210> 41
<211> 7
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 41
Arg Ala Ser Asn Leu Glu Ser
1 5
<210> 42
<211> 8
<212> PRT
<213> 小家鼠（Mus musculus）
<400> 42
Gln Gln Ser Lys Glu Tyr Pro Thr
1 5
<210> 43
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B2 pro-Vh
<400> 43
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Tyr Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 44
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 317-4B2 pro-Vk
<400> 44
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Glu Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 45
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B5 pro-Vh
<400> 45
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Tyr Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 46
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 317-4B5 pro-Vk
<400> 46
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Glu Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 47
<211> 354
<212> DNA
<213> 人工序列
<220>
<223> 317-1 cDNA-Vh
<400> 47
caggtgcagc tgcaggagtc gggaccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggtt ttcattaacc agctatggtg tacactggat ccggcagccc 120
ccagggaagg gactggagtg gctgggggtc atatgggccg gtggaagcac aaattataat 180
ccctccctca agagtcgact gaccatatca aaagacaact ccaagagcca ggtttccctg 240
aagatgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agcctatggt 300
aactactggt acatcgatgt ctggggccaa gggaccacgg tcaccgtctc ctca 354
<210> 48
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-1 pro-Vh
<400> 48
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 49
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 317-1 cDNA-Vk
<400> 49
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca aggccagcca gagtgtgagt aatgatgtag cttggtacca gcagaaacca 120
ggacagcctc ctaagctgct cattaactat gcatttcatc gcttcactgg ggtccctgac 180
cgattcagtg gcagcgggta tgggacagat ttcactctca ccatcagcag cctgcaggct 240
gaagatgtgg cagtttatta ctgtcaccag gcttatagtt ctccgtacac gtttggcggg 300
gggaccaagc tggagatcaa a 321
<210> 50
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 317-1 pro-Vk
<400> 50
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 51
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3B1 pro-Vh
<400> 51
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 52
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-3B1 pro-Vk
<400> 52
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 53
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3G1 pro-Vh
<400> 53
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 54
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-3G1 pro-Vk
<400> 54
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 55
<211> 342
<212> DNA
<213> 人工序列
<220>
<223> 326-1 cDNA-Vh
<400> 55
caggtgcagc tggtgcagag cggcagcgag ctgaagaagc ccggcgccag cgtgaaggtg 60
agctgcaagg ccagcggcta caccttcacc aactacggca tgaactgggt gagacaggcc 120
cccggccagg gcctggagtg gatgggctgg atcaacaaca acaacggcga gcccacctac 180
gcccagggct tcagaggcag attcgtgttc agcctggaca ccagcgccag caccgcctac 240
ctgcagatca gcagcctgaa gaccgaggac accgccgtgt acttctgcgc cagagacgtg 300
atggactact ggggccaggg caccaccgtg accgtgagca gc 342
<210> 56
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-1 pro-Vh
<400> 56
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Gly Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser
<210> 57
<211> 330
<212> DNA
<213> 人工序列
<220>
<223> 326-1 cDNA-Vk
<400> 57
gacattgtgc tgacccagtc tccagcctcc ttggccgtgt ctccaggaca gagggccacc 60
atcacctgca gagccagtga aagtgttgat aattatggct atagttttat gcactggtat 120
cagcagaaac caggacaacc tcctaaactc ctgatttacc gtgcatccaa cctagaatct 180
ggggtcccag ccaggttcag cggcagtggg tctaggaccg atttcaccct cacaattaat 240
cctgtggaag ctaatgatac tgcaaattat tactgtcagc aaagtaaaga atatccgacg 300
ttcggcggag ggaccaaggt ggagatcaaa 330
<210> 58
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-1 pro-Vk
<400> 58
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 59
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 317-1 H-CDR2 或 CDR-H2
<400> 59
Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 60
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 317-4B2 H-CDR2 或 CDR-H2
<400> 60
Val Ile Tyr Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 61
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 317-4B2 L-CDR1 或 CDR-L1
<400> 61
Lys Ser Ser Glu Ser Val Ser Asn Asp Val Ala
1 5 10
<210> 62
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 326-1 H-CDR2 或 CDR-H2
<400> 62
Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Gly Phe Arg
1 5 10 15
Gly
<210> 63
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 326-3G1 H-CDR2 或 CDR-H2
<400> 63
Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Asp Phe Arg
1 5 10 15
Gly
<210> 64
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3A1 pro-Vh
<400> 64
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 65
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3C1 pro-Vh
<400> 65
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 66
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3E1 pro-Vh
<400> 66
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 67
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3F1 pro-Vh
<400> 67
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 68
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3G1 pro-Vh
<400> 68
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 69
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3H1 pro-Vh
<400> 69
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 70
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-3I1 pro-Vh
<400> 70
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 71
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B1 pro-Vh
<400> 71
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 72
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B3 pro-Vh
<400> 72
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Asn Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Trp Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 73
<211> 118
<212> PRT
<213> 人工序列
<220>
<223> 317-4B4 pro-Vh
<400> 73
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30
Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Tyr Gly Asn Tyr Pro Tyr Ile Asp Val Trp Gly Gln Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 74
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 317-4A2 pro-Vk
<400> 74
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Ser Asn Asp
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Asn Tyr Ala Phe His Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys His Gln Ala Tyr Ser Ser Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 75
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3A1 pro-Vh
<400> 75
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Gly Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 76
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3C1 pro-Vh
<400> 76
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser
<210> 77
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3D1 pro-Vh
<400> 77
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Gly Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 78
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3E1 pro-Vh
<400> 78
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser
<210> 79
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3F1 pro-Vh
<400> 79
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asn Gly Glu Pro Thr Tyr Ala Gln Gly Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser
<210> 80
<211> 114
<212> PRT
<213> 人工序列
<220>
<223> 326-3B N55D pro-Vh
<400> 80
Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Asn Asn Asp Gly Glu Pro Thr Tyr Ala Gln Asp Phe
50 55 60
Arg Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Val Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
<210> 81
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-4A1 pro-Vk
<400> 81
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Glu Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 82
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 326-4A2 pro-Vk
<400> 82
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly
1 5 10 15
Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr
20 25 30
Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn
65 70 75 80
Pro Val Glu Ala Asn Asp Thr Ala Asn Tyr Tyr Cys Gln Gln Ser Lys
85 90 95
Glu Tyr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 83
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt1 pro
<400> 83
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 84
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt2 pro
<400> 84
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Pro Val Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 85
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt6 pro
<400> 85
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Pro Val Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Ala Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 86
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt8 pro
<400> 86
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Pro Val Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Thr Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 87
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt9 pro
<400> 87
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Pro Val Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Ala Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 88
<211> 327
<212> PRT
<213> 人工序列
<220>
<223> huIgG4mt10 pro
<400> 88
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Pro Val Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Ala Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Val His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
<210> 89
<211> 367
<212> PRT
<213> 人工序列
<220>
<223> OS8 pro
<400> 89
Met Glu Arg His Trp Ile Phe Leu Leu Leu Leu Ser Val Thr Ala Gly
1 5 10 15
Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg
20 25 30
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45
Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
50 55 60
Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn
65 70 75 80
Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser
85 90 95
Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp
115 120 125
Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser
145 150 155 160
Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys
165 170 175
Ser Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser
180 185 190
Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser
195 200 205
Gly Val Pro Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser
210 215 220
Leu Thr Ile Ser Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
225 230 235 240
Gln Gln Trp Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu
245 250 255
Glu Ile Asn Ser Ser Val Val Pro Val Leu Gln Lys Val Asn Ser Thr
260 265 270
Thr Thr Lys Pro Val Leu Arg Thr Pro Ser Pro Val His Pro Thr Gly
275 280 285
Thr Ser Gln Pro Gln Arg Pro Glu Asp Cys Arg Pro Arg Gly Ser Val
290 295 300
Lys Gly Thr Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
305 310 315 320
Leu Ala Gly Ile Cys Val Ala Leu Leu Leu Ser Leu Ile Ile Thr Leu
325 330 335
Ile Cys Tyr His Arg Ser Arg Lys Arg Val Cys Lys Cys Pro Arg Pro
340 345 350
Leu Val Arg Gln Glu Gly Lys Pro Arg Pro Ser Glu Lys Ile Val
355 360 365
<210> 90
<211> 304
<212> PRT
<213> 人工序列
<220>
<223> P3Z pro
<400> 90
Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln
1 5 10 15
Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp
20 25 30
Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp
35 40 45
Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val
50 55 60
Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
65 70 75 80
Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg
85 90 95
Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg
100 105 110
Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu
115 120 125
Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val
130 135 140
Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro
145 150 155 160
Arg Pro Ala Gly Gln Phe Gln Thr Leu Val Val Gly Val Val Gly Gly
165 170 175
Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu Ala Val Ile Arg
180 185 190
Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
195 200 205
Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
210 215 220
Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
225 230 235 240
Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
245 250 255
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
260 265 270
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
275 280 285
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
290 295 300

Claims (16)

1.一种多核苷酸，所述多核苷酸编码特异性地结合至PD-1的抗体或其抗原结合片段的重链可变区和轻链可变区，其中所述重链可变区包含根据SEQID NO:31的重链互补决定区(CDR)1，根据SEQ ID NO:32的重链CDR2以及根据SEQ ID NO:33的重链CDR3，并且所述轻链可变区包含根据SEQID NO:34的轻链CDR1，根据SEQ ID NO:35的轻链CDR2以及根据SEQ IDNO:36的轻链CDR3。
2.根据权利要求1所述的多核苷酸，其中所述抗体或其抗原结合片段包含根据SEQ IDNO:24的重链可变区和根据SEQ ID NO:26的轻链可变区。
3.根据权利要求1所述的多核苷酸，其中所述多核苷酸包含根据SEQ ID NO:23的序列。
4.根据权利要求1所述的多核苷酸，其中所述多核苷酸包含根据SEQ ID NO:25的序列。
5.根据权利要求1所述的多核苷酸，其中所述多核苷酸包含SEQ ID NO:23和SEQ IDNO:25。
6.根据权利要求1所述的多核苷酸，其中所述抗体是单克隆抗体。
7.根据权利要求6所述的多核苷酸，其中所述单克隆抗体具有IgG4重链。
8.一种编码结合至PD-1的人源化单克隆抗体的多核苷酸，其中所述抗体包含重链氨基酸序列和轻链氨基酸序列，所述重链氨基酸序列包含SEQ ID NO:24的重链可变区和SEQ IDNO:88的重链IgG4 Fc区，并且所述轻链氨基酸序列包含以NCBI登录号P01834存放的轻链IgκC区的氨基酸序列和SEQ ID NO:26的轻链可变区。
9.一种结合PD-1的人源化单克隆抗体，所述抗体包含：SEQ ID NO:24的重链可变区、SEQ ID NO:88的重链IgG4 Fc区、以NCBI登录号P01834存放的轻链IgκC区、以及SEQ ID NO:26的轻链可变区。
10.根据权利要求9所述的结合PD-1的人源化单克隆抗体，其中所述抗体由以下各区域组成：SEQ ID NO:24的重链可变区、SEQ ID NO:88的重链IgG4Fc区、以NCBI登录号P01834存放的轻链IgκC区、以及SEQ ID NO:26的轻链可变区。
11.包含根据权利要求1所述的多核苷酸的表达载体。
12.包含根据权利要求11的表达载体的宿主细胞。
13.一种制备抗PD-1抗体或其抗原结合片段的方法，所述方法包括：在其中所述抗体或其抗原结合片段产生的条件下培养包含编码所述抗体或其抗原结合片段的一个或多个核酸的细胞，其中所述抗体或其抗原结合片段包含如SEQ ID NO:31中所示的重链互补决定区(CDR)1、如SEQ ID NO:32中所示的重链CDR2、如SEQ ID NO:33中所示的重链CDR3、如SEQ IDNO:34中所示的轻链CDR1、如SEQ ID NO:35中所示的轻链CDR2、和如SEQID NO:36中所示的轻链CDR3；以及回收所述抗体或其抗原结合片段。
14.根据权利要求13所述的方法，其中所述抗体或其抗原结合片段的重链在所述细胞中的第一表达载体上编码，并且所述抗体或其抗原结合片段的轻链在所述细胞中的第二表达载体上编码。
15.根据权利要求13所述的方法，其中所述抗体或其抗原结合片段的重链和轻链在相同表达载体上编码。
16.根据权利要求13所述的方法，所述方法进一步包括在回收所述抗体之后纯化所述抗体或其片段。
CN202011322092.7A 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途 Active CN112552401B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011322092.7A CN112552401B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201380079581.6A CN105531288B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
PCT/CN2013/083467 WO2015035606A1 (en) 2013-09-13 2013-09-13 Anti-pd1 antibodies and their use as therapeutics and diagnostics
CN202011322092.7A CN112552401B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380079581.6A Division CN105531288B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Publications (2)

Publication Number Publication Date
CN112552401A CN112552401A (zh) 2021-03-26
CN112552401B true CN112552401B (zh) 2023-08-25

Family

ID=50736425

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201710207300.0A Active CN107011441B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN202011322092.7A Active CN112552401B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN201380079581.6A Active CN105531288B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN202011322081.9A Active CN112457403B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN201710208535.1A Active CN107090041B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN201810552595.XA Active CN108715615B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710207300.0A Active CN107011441B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201380079581.6A Active CN105531288B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN202011322081.9A Active CN112457403B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN201710208535.1A Active CN107090041B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN201810552595.XA Active CN108715615B (zh) 2013-09-13 2013-09-13 抗pd1抗体及其作为治疗剂与诊断剂的用途

Country Status (30)

Country Link
US (9) US8735553B1 (zh)
EP (3) EP3044234B9 (zh)
JP (1) JP6623353B2 (zh)
KR (1) KR102100419B1 (zh)
CN (6) CN107011441B (zh)
AU (3) AU2013400609B9 (zh)
BR (1) BR112016005408B1 (zh)
CA (3) CA3080200A1 (zh)
CY (2) CY1125652T1 (zh)
DK (2) DK3044234T3 (zh)
EA (1) EA034666B1 (zh)
ES (2) ES2927567T3 (zh)
FR (1) FR24C1001I1 (zh)
HK (1) HK1217501A1 (zh)
HR (1) HRP20221262T1 (zh)
HU (3) HUE060420T2 (zh)
IL (5) IL296026B1 (zh)
LT (1) LT3702373T (zh)
MX (1) MX2016003292A (zh)
NL (1) NL301252I2 (zh)
NO (1) NO2023045I1 (zh)
NZ (1) NZ718643A (zh)
PL (2) PL3702373T3 (zh)
PT (2) PT3702373T (zh)
RS (1) RS63571B9 (zh)
SG (1) SG11201601844TA (zh)
SI (1) SI3702373T1 (zh)
TW (1) TWI636995B (zh)
WO (1) WO2015035606A1 (zh)
ZA (1) ZA201601953B (zh)

Families Citing this family (590)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
BR112014012628B8 (pt) 2011-12-31 2023-01-17 Beigene Ltd Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
HUE031980T2 (en) 2013-04-25 2017-08-28 Beigene Ltd Condensed heterocyclic compounds as protein kinase inhibitors
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CA2922655A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
HUE039012T2 (hu) 2013-09-06 2018-12-28 Aurigene Discovery Tech Ltd Gyûrûs peptidomimetikus vegyületek, mint immunomodulátorok
JP6521977B2 (ja) 2013-09-06 2019-05-29 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，２，４−オキサジアゾール誘導体
MX2016003292A (es) 2013-09-13 2016-06-24 Beigene Ltd Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos.
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
LT3081576T (lt) 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
US10106607B2 (en) 2013-12-20 2018-10-23 Intervet Inc. Caninized antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106604742B (zh) * 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
AU2015292678B2 (en) * 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
ES2847311T3 (es) * 2014-08-05 2021-08-02 MabQuest SA Reactivos inmunológicos que se unen a PD-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
WO2016077397A2 (en) * 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
ES2881484T3 (es) * 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anticuerpos anti-PD-1
US11639385B2 (en) 2014-12-22 2023-05-02 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
WO2016117618A1 (ja) * 2015-01-20 2016-07-28 国立大学法人九州大学 慢性炎症性脱髄性多発神経炎の診断方法、キット及びバイオマーカー
EP3267984B1 (en) 2015-03-10 2021-11-24 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
CN107743495B (zh) 2015-03-23 2021-05-14 拜耳制药股份公司 抗ceacam6抗体及其用途
CN106146667B (zh) * 2015-03-27 2020-06-19 四川大学华西医院 一种Exendin-4融合蛋白及其制备方法与用途
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN114380909A (zh) 2015-03-30 2022-04-22 斯特库比股份有限公司 特异性针对糖基化的pd-l1的抗体及其使用方法
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3283107B1 (en) 2015-04-17 2020-05-27 Bristol-Myers Squibb Company Compositions comprising a combination of ipilimumab and nivolumab
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
KR102138209B1 (ko) 2015-05-06 2020-07-28 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
WO2016179472A2 (en) * 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
CN113603784A (zh) 2015-05-29 2021-11-05 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
RS61532B1 (sr) 2015-07-14 2021-04-29 Bristol Myers Squibb Co Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
KR20180036974A (ko) 2015-07-16 2018-04-10 바이오엑셀 테라퓨틱스 인코포레이티드 면역조절을 이용하는 암의 치료를 위한 신규한 접근법
GEP20227419B (en) 2015-07-30 2022-10-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
KR20180035906A (ko) 2015-08-07 2018-04-06 피어이스 파마슈티컬즈 게엠베하 Lag-3 및 pd-1에 특이적인 신규 융합 폴리펩타이드
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CA2994895A1 (en) 2015-08-25 2017-03-02 Beigene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
MX2018002315A (es) 2015-09-01 2018-04-11 Agenus Inc Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
ES2839212T3 (es) 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Métodos para determinar el estado metabólico de linfomas B
AR106184A1 (es) * 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
SG10201913591SA (en) * 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
US11594135B2 (en) 2015-11-02 2023-02-28 Memgen, Inc. Methods of CD40 activation and immune checkpoint blockade
KR20180069070A (ko) 2015-11-03 2018-06-22 얀센 바이오테크 인코포레이티드 Tim-3과 특이적으로 결합하는 항체 및 그의 용도
JP2018532810A (ja) 2015-11-07 2018-11-08 マルチビア インコーポレイテッド がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
TWI795347B (zh) 2015-11-18 2023-03-11 美商必治妥施貴寶公司 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
EP3383412A4 (en) * 2015-12-02 2019-06-05 Stcube, Inc. SPECIFIC ANTIBODIES OF GLYCOSYLATED PD-1 PROTEIN AND METHODS OF USE
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
PT3394093T (pt) 2015-12-23 2022-05-30 Modernatx Inc Métodos de utilização de polinucleotídeos que codificam ligandos ox40
ES2837155T3 (es) 2016-01-04 2021-06-29 Inst Nat Sante Rech Med Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
PL3402503T3 (pl) 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
AU2017208819B2 (en) 2016-01-22 2023-10-19 MabQuest SA PD1 specific antibodies
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3436481B1 (en) 2016-03-29 2021-06-30 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
EP3449017B1 (en) 2016-04-29 2021-12-22 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
WO2017200796A1 (en) 2016-05-17 2017-11-23 Albert Einstein College Of Medicine, Inc. Engineered pd-1 variants
KR102482867B1 (ko) 2016-05-18 2023-01-02 모더나티엑스, 인크. 면역 조정 폴리펩타이드를 암호화하는 mRNA의 조합물 및 이의 용도
MX2018013509A (es) 2016-05-18 2019-03-28 Modernatx Inc Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos.
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
JP7267012B2 (ja) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド 抗ｔｉｍ－３抗体及びその使用方法
FI3464368T3 (fi) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
KR20230038318A (ko) 2016-06-02 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
KR102515509B1 (ko) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
EP3464369A1 (en) 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
KR20190015407A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
DK3471722T3 (da) * 2016-06-17 2023-12-04 Univ Pennsylvania Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
DK3476865T3 (da) 2016-06-28 2023-12-18 Biocytogen Pharmaceuticals Beijing Co Ltd Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
AU2017293423B2 (en) * 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
US10927117B2 (en) 2016-08-16 2021-02-23 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
DK3500299T3 (da) 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
TW202246347A (zh) 2016-08-26 2022-12-01 英屬開曼群島商百濟神州有限公司 抗tim-3抗體及其用途
EP3858365B1 (en) 2016-09-01 2024-01-31 Chimera Bioengineering Inc. Gold optimized car t-cells
WO2018048936A1 (en) 2016-09-06 2018-03-15 Incelldx, Inc. Methods of detecting per cell pd-l1 expression and uses thereof
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
CN109923211A (zh) 2016-09-08 2019-06-21 蓝鸟生物公司 Pd-1归巢核酸内切酶变体、组合物及使用方法
EP3514177B1 (en) 2016-09-14 2023-07-26 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to pd-1 and functional fragment thereof
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
TWI806840B (zh) * 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
CN110267651B (zh) 2016-09-27 2023-09-01 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
KR102661905B1 (ko) 2016-10-12 2024-04-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tusc2 면역요법을 위한 방법 및 조성물
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
WO2018081621A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018085358A1 (en) 2016-11-02 2018-05-11 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
JP7039582B2 (ja) 2016-11-03 2022-03-22 ブリストル－マイヤーズ スクイブ カンパニー 活性化可能な抗ｃｔｌａ－４抗体およびその使用
EP3538112A4 (en) 2016-11-09 2020-09-02 Musc Foundation for Research Development CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
KR20190103226A (ko) 2017-01-13 2019-09-04 아게누스 인코포레이티드 Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
TWI832600B (zh) 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
US20200237874A1 (en) 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
TW202313678A (zh) 2017-01-20 2023-04-01 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2018133842A1 (zh) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
CN108341871A (zh) 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
WO2018146612A1 (en) 2017-02-10 2018-08-16 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
WO2018157162A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
KR20190124750A (ko) 2017-02-28 2019-11-05 사노피 치료적 rna
EP3589652A4 (en) 2017-03-04 2021-05-05 Xiangtan Tenghua Bioscience RECOMBINANT ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH 1 (PD-1) AND THEIR USES
WO2018175279A2 (en) * 2017-03-20 2018-09-27 The General Hospital Corporation MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
US20210186982A1 (en) 2017-03-24 2021-06-24 Universite Nice Sophia Antipolis Methods and compositions for treating melanoma
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR20190133213A (ko) 2017-03-31 2019-12-02 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
CA3057744A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
US11492403B2 (en) 2017-04-20 2022-11-08 Dana-Farber Cancer Institute, Inc. Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
SI3618863T1 (sl) 2017-05-01 2023-12-29 Agenus Inc. Protitelesa proti tigitu in načini uporabe njih
WO2018204303A1 (en) * 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
SG10202111336RA (en) 2017-06-01 2021-11-29 Compugen Ltd Triple combination antibody therapies
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
CA3066518A1 (en) * 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
EP3645037A1 (en) 2017-06-27 2020-05-06 Novartis AG Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3421494A1 (en) 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
AU2018301681B2 (en) 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
US11899017B2 (en) 2017-07-28 2024-02-13 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
KR20200032180A (ko) 2017-07-28 2020-03-25 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11787859B2 (en) 2017-08-28 2023-10-17 Bristol-Myers Squibb Company TIM-3 antagonists for the treatment and diagnosis of cancers
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
KR20200039796A (ko) 2017-08-31 2020-04-16 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
KR102651946B1 (ko) 2017-08-31 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
CN111278854A (zh) 2017-09-04 2020-06-12 艾吉纳斯公司 与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
SG11202003081WA (en) 2017-10-11 2020-05-28 Aurigene Discovery Tech Ltd Crystalline forms of 3-substituted 1,2,4-oxadiazole
AU2018346955A1 (en) 2017-10-13 2020-04-30 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
KR101982001B1 (ko) * 2017-10-13 2019-05-27 한국과학기술원 동종 또는 이종 거부반응을 이용한 항 pd-1 또는 항 pd-l1 항체 선별 방법
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
JP7254821B2 (ja) 2017-10-16 2023-04-10 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
JP2021502344A (ja) 2017-11-06 2021-01-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
EP3707510B1 (en) 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
JP7378395B2 (ja) 2017-11-06 2023-11-13 オーリジーン オンコロジー リミテッド 免疫調節のためのコンジョイントセラピー
WO2019094265A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Pd1 polypeptide binding molecules
SG11202003477QA (en) 2017-11-14 2020-05-28 Pfizer Ezh2 inhibitor combination therapies
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
KR20200089718A (ko) 2017-11-20 2020-07-27 아리아젠, 인크. 인돌 화합물 및 이의 용도
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
CN111801334B (zh) * 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
US11667713B2 (en) * 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
KR20200120641A (ko) * 2018-01-15 2020-10-21 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
BR112020014574A2 (pt) 2018-01-22 2020-12-08 Bristol-Myers Squibb Company Composições e métodos para o tratamento do câncer
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019157124A1 (en) 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
WO2019157353A1 (en) * 2018-02-09 2019-08-15 Beigene, Ltd. Immunotherapy for urothelial carcinoma
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
CA3091502A1 (en) 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
EP3762397B1 (en) 2018-03-08 2024-05-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN112020510A (zh) 2018-03-19 2020-12-01 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
MX2020009861A (es) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
DE112019001543T5 (de) 2018-03-25 2020-12-17 Snipr Biome Aps. Behandlung und verhinderung von mikrobiellen infektionen
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN112088000A (zh) 2018-03-27 2020-12-15 得克萨斯州大学系统董事会 具有针对携带her2外显子19突变之癌细胞的抗肿瘤活性的化合物
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
CN112292399A (zh) 2018-04-04 2021-01-29 百时美施贵宝公司 抗cd27抗体及其用途
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019209995A2 (en) 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
ES2971122T3 (es) 2018-04-25 2024-06-03 Innate Tumor Immunity Inc Moduladores de NLRP3
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
EA202092136A1 (ru) 2018-05-07 2021-03-22 Генмаб А/С Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
US11136394B2 (en) 2018-05-17 2021-10-05 Nanjing Leads Biolabs Co., Ltd. Antibody binding PD-1 and use thereof
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3810109A4 (en) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. COMPOSITIONS AND METHODS FOR INHIBITING CD73
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
CN108752460B (zh) * 2018-06-07 2022-05-10 江苏东抗生物医药科技有限公司 一种高亲和力的pd-1膜外区突变体的融合蛋白及其药物组合物和用途
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
FI3820573T3 (fi) 2018-07-10 2023-11-01 Novartis Ag 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019302642A1 (en) 2018-07-10 2021-02-25 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
WO2020015722A1 (en) * 2018-07-19 2020-01-23 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies, dosages and uses thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP3826660A1 (en) 2018-07-26 2021-06-02 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
JP2021534180A (ja) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
ES2974964T3 (es) 2018-08-16 2024-07-02 Innate Tumor Immunity Inc Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
JP7364663B2 (ja) 2018-08-16 2023-10-18 イネイト・テューマー・イミュニティ・インコーポレイテッド イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター
TW202026423A (zh) 2018-08-24 2020-07-16 法商賽諾菲公司 用於實體瘤癌症的治療性ｒｎａ
CN112955221A (zh) 2018-08-27 2021-06-11 皮里斯制药有限公司 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
JP2021535169A (ja) 2018-09-03 2021-12-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
JP2022501361A (ja) 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用
CN112930114B (zh) 2018-09-20 2023-10-03 艾欧凡斯生物治疗公司 由冷冻保存的肿瘤样品扩增til
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
US20210348238A1 (en) 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CN109470806A (zh) * 2018-10-19 2019-03-15 张骐 通过二维液相对单抗类产品细胞株进行高通量筛选的方法
JP2022512750A (ja) 2018-10-19 2022-02-07 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫に対する併用療法
EP3870609A1 (en) 2018-10-23 2021-09-01 Bristol-Myers Squibb Company Methods of treating tumor
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
US20220010017A1 (en) 2018-11-14 2022-01-13 Bayer Aktiengesellschaft Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
WO2020106695A1 (en) 2018-11-19 2020-05-28 Ariagen, Inc. Methods of treating cancer
EP3883969A4 (en) 2018-11-19 2022-11-16 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-PD-1 ANTIBODIES AND THEIR USES
US20230183379A1 (en) 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
CA3121210A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
KR102195135B1 (ko) * 2018-12-07 2020-12-24 한국과학기술원 면역조절제의 스크리닝 방법
WO2020123375A1 (en) * 2018-12-10 2020-06-18 Bluebird Bio, Inc. Pdcd-1 homing endonuclease variants
MX2021006831A (es) 2018-12-11 2021-07-02 Theravance Biopharma R&D Ip Llc Inhibidores de alk5.
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
SG11202104699TA (en) 2018-12-21 2021-07-29 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
KR20210106531A (ko) 2018-12-21 2021-08-30 에임 이뮤노테크 인코포레이티드 암 치료를 위한 조성물 및 방법
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
BR112021012066A2 (pt) 2018-12-21 2021-11-03 Onxeo Novas moléculas de ácido nucleico conjugadas e seus usos
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CN111423510B (zh) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
WO2020150116A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP7373571B2 (ja) 2019-01-14 2023-11-02 イネイト・テューマー・イミュニティ・インコーポレイテッド がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
EP3911417B1 (en) 2019-01-14 2022-10-26 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators , for use in the treatment of cancer
CN113286786A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
CN113507963A (zh) 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
CN113366316A (zh) 2019-01-30 2021-09-07 国家医疗保健研究所 用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
MX2021009562A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN113490528A (zh) 2019-02-15 2021-10-08 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN113891748A (zh) 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
JP2022527345A (ja) 2019-04-03 2022-06-01 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
EP3956327A1 (en) 2019-04-15 2022-02-23 Ariagen, Inc. Chiral indole compounds and their use
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3134522A1 (en) 2019-04-19 2020-10-22 Genentech, Inc. Anti-mertk antibodies and their methods of use
EP3963109A1 (en) 2019-04-30 2022-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN114144514A (zh) 2019-05-09 2022-03-04 富士胶片细胞动力公司 产生肝细胞的方法
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
EP3968971A1 (en) 2019-05-17 2022-03-23 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
EP3976090A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
MX2021014932A (es) 2019-06-03 2022-04-06 Univ Chicago Métodos y composiciones para tratar cáncer con portadores de fármacos que se enlazan al colágeno.
AU2020286523A1 (en) 2019-06-03 2022-02-03 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
WO2020255011A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
WO2020255009A2 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CN117447596A (zh) * 2019-06-30 2024-01-26 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
CN112225809B (zh) * 2019-06-30 2023-09-05 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TW202120550A (zh) 2019-08-08 2021-06-01 日商小野藥品工業股份有限公司 雙特異性蛋白質
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2022548212A (ja) * 2019-09-11 2022-11-17 ベイジーン リミテッド マルチチロシンキナーゼ阻害剤及び免疫チェックポイント阻害剤を含む組合せを用いた癌の治療
CA3151022A1 (en) 2019-09-17 2021-03-25 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
KR20220100860A (ko) 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. 질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물
EP4031531A1 (en) 2019-09-17 2022-07-27 Bial-R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022549273A (ja) 2019-09-22 2022-11-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
CN114728046A (zh) 2019-09-25 2022-07-08 思进公司 联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症
BR112022005655A2 (pt) 2019-09-25 2022-09-06 Bristol Myers Squibb Co Biomarcador compósito para terapia para câncer
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
EP4037714A1 (en) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CA3157889A1 (en) 2019-10-17 2021-04-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for diagnosing nasal intestinal type adenocarcinomas
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
BR112022007720A2 (pt) 2019-10-24 2022-08-23 Prometheus Biosciences Inc Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
US20220380765A1 (en) 2019-11-02 2022-12-01 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
CN115298549A (zh) 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
US20220411499A1 (en) 2019-11-08 2022-12-29 Bristol-Myers Squibb Company LAG-3 Antagonist Therapy for Melanoma
CN112794906B (zh) * 2019-11-13 2022-04-05 合肥瀚科迈博生物技术有限公司 抗4-1bb的单链抗体及其应用
EP4058435A1 (en) 2019-11-13 2022-09-21 Genentech, Inc. Therapeutic compounds and methods of use
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
EP4061850A4 (en) * 2019-11-21 2024-03-20 BeiGene, Ltd. METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-PD1 OR ANTI-PDL1 ANTIBODIES
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
AU2020385400A1 (en) 2019-11-22 2022-06-09 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
AU2020408198A1 (en) 2019-12-19 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US20230044381A1 (en) * 2019-12-20 2023-02-09 Guangdong Feipeng Pharmaceutical Co., Ltd Anti-human programmed death-1 monoclonal antibody
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
US20230348458A1 (en) 2020-01-10 2023-11-02 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2021144426A1 (en) 2020-01-17 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
MX2022008763A (es) 2020-01-17 2022-07-27 Novartis Ag Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
CN115397859A (zh) 2020-01-30 2022-11-25 Ona疗法有限公司 治疗癌症和癌症转移的联合疗法
AU2021212197A1 (en) 2020-01-31 2022-08-04 BioNTech SE Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
IL295626A (en) 2020-02-28 2022-10-01 Novartis Ag A triple drug combination that includes dabrafenib, an erk inhibitor and a raf inhibitor
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
MX2022010912A (es) 2020-03-06 2022-11-09 Celgene Quanticel Res Inc Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc).
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー がんを処置するための抗ｃｃｒ８抗体
CN115443269A (zh) 2020-03-31 2022-12-06 施万生物制药研发Ip有限责任公司 经取代的嘧啶和使用方法
KR20230004635A (ko) 2020-04-21 2023-01-06 노파르티스 아게 Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법
CN115997008A (zh) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
KR102623161B1 (ko) * 2020-10-08 2024-01-09 고려대학교 산학협력단 Pd-l1 친화도가 증가된 pd-1 변이체
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
US20230233474A1 (en) 2020-05-28 2023-07-27 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116209459A (zh) 2020-06-26 2023-06-02 美国安进公司 Il-10突变蛋白及其融合蛋白
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US20230266332A1 (en) 2020-07-28 2023-08-24 Inserm (Institut National De La Santè Et De La Recherch Médicale) Methods and compositions for preventing and treating a cancer
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022047189A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023538955A (ja) 2020-08-31 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在シグネチャーおよび免疫療法
AU2021337223A1 (en) 2020-09-02 2023-03-16 Msd International Gmbh Combination therapy of a PD-1 antagonist and an antagonist for VEGFR-2 for treating patients with cancer
BR112023005377A2 (pt) 2020-09-24 2023-04-25 Merck Sharp & Dohme Llc Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
CN112285224A (zh) * 2020-10-02 2021-01-29 朱吉安 一种抗pd-1单克隆抗体药物的质量标准检测方法
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
EP4236960A1 (en) 2020-10-28 2023-09-06 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW202225191A (zh) 2020-11-04 2022-07-01 美商建南德克公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之皮下給藥
US20220153842A1 (en) 2020-11-04 2022-05-19 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4244392A1 (en) 2020-11-16 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for predicting and treating uveal melanoma
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
MX2023005528A (es) 2020-11-17 2023-06-23 Seagen Inc Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1.
US20220162288A1 (en) 2020-11-25 2022-05-26 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
CA3202523A1 (en) 2020-12-02 2022-06-09 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20220218614A1 (en) 2020-12-04 2022-07-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
JP2024503265A (ja) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物およびその使用の方法
JP2024503480A (ja) 2021-01-19 2024-01-25 ウィリアム マーシュ ライス ユニバーシティ ポリペプチドの骨特異的送達法
US20220249639A1 (en) 2021-01-22 2022-08-11 Dcprime B.V. Methods of tumor vaccination
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
IL305795A (en) * 2021-03-10 2023-11-01 B G Negev Technologies & Applications Ltd At Ben Gurion Univ Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
US20240165094A1 (en) 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4346887A1 (en) 2021-05-25 2024-04-10 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
WO2022256538A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
KR20240022608A (ko) 2021-06-18 2024-02-20 젠자임 코포레이션 항-tgf-베타 항체 제형 및 이의 용도
CA3223534A1 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
KR20240042476A (ko) 2021-07-30 2024-04-02 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
IL310773A (en) 2021-09-02 2024-04-01 Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts Anti-CECAM6 antibodies with reduced side effects
EP4398889A1 (en) 2021-09-10 2024-07-17 Leap Therapeutics, Inc. Combination therapy
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
IL311790A (en) 2021-10-05 2024-05-01 Chang Hao Ming Natural killer cells and methods of their use
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
CA3234647A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co BCMA designated preparations and methods for their use
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
KR20240099331A (ko) 2021-10-28 2024-06-28 라이엘 이뮤노파마, 인크. 면역 세포를 배양하기 위한 방법
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
IL312249A (en) 2021-11-12 2024-06-01 Advanced Accelerator Applications Combined treatment for lung cancer
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
US20230202984A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
AU2022409713A1 (en) 2021-12-16 2024-06-20 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023133424A2 (en) * 2022-01-05 2023-07-13 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
US20230326022A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
TW202345902A (zh) * 2022-04-14 2023-12-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023241659A1 (en) * 2022-06-16 2023-12-21 Beigene, Ltd. Methods of treating lymphoma using anti-tigit antibodies
WO2024012364A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024012584A1 (en) * 2022-07-15 2024-01-18 Beigene Switzerland Gmbh Methods of cancer treatment using anti-tigit antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024041652A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment
WO2024041651A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792533A (fr) 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
JP2778921B2 (ja) 1994-11-18 1998-07-23 三共株式会社 イミダゾピラゾール誘導体
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
BR0013542A (pt) 1999-08-23 2002-05-14 Dana Farber Cancer Inst Inc Moléculas b7-4 e usos para as mesmas
JP2003508401A (ja) 1999-08-27 2003-03-04 アボット・ラボラトリーズ Ｃｏｘ−２阻害薬として有用なスルホニルフェニルピラゾール化合物
ATE247657T1 (de) 1999-09-17 2003-09-15 Basf Ag Pyrazolopyrimidine als arzneimittel
CA2406993A1 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US20020094989A1 (en) 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
JP3871326B2 (ja) 2000-11-15 2007-01-24 小野薬品工業株式会社 Ｐｄ−１欠損マウスおよびその用途
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
DE60207390T2 (de) 2001-03-09 2006-07-20 Pfizer Products Inc., Groton Entzündungshemmende benzimidazolverbindungen
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
JPWO2003004497A1 (ja) 2001-07-05 2004-10-28 住友製薬株式会社 新規複素環化合物
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
ZA200500782B (en) 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
ES2367430T3 (es) * 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
EP1651648A4 (en) 2003-07-29 2009-09-02 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
ES2387312T3 (es) 2004-09-22 2012-09-20 Kyowa Hakko Kirin Co., Ltd. Anticuerpos IgG4 humanos estabilizados
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
CN101213297B (zh) * 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
CA2981431C (en) 2005-06-08 2021-04-13 Dana-Farber Cancer Institute Inc. Use of compounds that reduce activity or expression of programmed cell death-1 to treat lymphoma
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
JP2009506123A (ja) 2005-08-29 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
WO2007026720A1 (ja) 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
KR20080049758A (ko) 2005-09-01 2008-06-04 아스텔라스세이야쿠 가부시키가이샤 통증 치료용으로 사용되는 피리다지논 유도체
EP1957460A1 (en) 2005-12-08 2008-08-20 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007087068A2 (en) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
CA2630344C (en) * 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
PE20080069A1 (es) 2006-05-15 2008-02-22 Merck & Co Inc Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
CA2858520A1 (en) 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
CN102887900B (zh) 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
US20100087464A1 (en) 2006-10-06 2010-04-08 Irm Llc Protein kinase inhibitors and methods for using thereof
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2688275A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2426109B1 (en) 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
EP2242749B1 (en) 2008-02-05 2013-04-10 F. Hoffmann-La Roche AG Novel pyridinones and pyridazinones
WO2009100309A2 (en) * 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2554615T3 (es) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR101523451B1 (ko) 2008-07-02 2015-05-27 에프. 호프만-라 로슈 아게 키나아제 억제제로서의 신규 페닐피라지논
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
MX2010013190A (es) 2008-07-18 2010-12-20 Hoffmann La Roche Fenilimidazopirazinas novedosas.
WO2010011837A1 (en) 2008-07-24 2010-01-28 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
MX2011002484A (es) 2008-09-05 2011-09-26 Avila Therapeutics Inc Algoritmo para diseñar inhibidores irreversibles.
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
MX349463B (es) * 2008-09-26 2017-07-31 Univ Emory Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
HUE028582T2 (en) * 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
EP3192811A1 (en) * 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
SG175287A1 (en) 2009-04-24 2011-11-28 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK2473049T3 (en) 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
ES2617281T3 (es) * 2009-10-28 2017-06-16 Janssen Biotech, Inc. Anticuerpos anti-glp-1r y sus usos
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CN102711810B (zh) * 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
LT2536745T (lt) * 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
WO2011120134A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
NZ604004A (en) 2010-05-07 2014-06-27 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
TWI535716B (zh) 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
SG186378A1 (en) 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
US20120100166A1 (en) * 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
BR112013007506A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridinonas/pirazinonas - métodos de criação e de uso
KR101864908B1 (ko) 2010-09-01 2018-06-05 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
PT2654790T (pt) * 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
PL2691112T3 (pl) * 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2760174A1 (en) 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
EA201391558A1 (ru) 2011-04-20 2014-05-30 Глэксо Груп Лимитед Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
SI2699264T1 (en) * 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind B7-H1 and PD-1
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
PL2718322T3 (pl) * 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
ES2923760T3 (es) 2011-06-10 2022-09-30 Merck Patent Gmbh Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de BTK
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
EA026924B1 (ru) * 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
RU2014153675A (ru) * 2012-07-03 2016-08-27 Янссен Альцгеймер Иммунотерапи Антитела к с-концевым и центральным эпитопам а-бета
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US20140377269A1 (en) * 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AU2014218915B2 (en) * 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
WO2014152195A1 (en) * 2013-03-15 2014-09-25 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
HUE031980T2 (en) 2013-04-25 2017-08-28 Beigene Ltd Condensed heterocyclic compounds as protein kinase inhibitors
US9676853B2 (en) * 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
MX2016003292A (es) 2013-09-13 2016-06-24 Beigene Ltd Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos.
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106687446B (zh) 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016025720A1 (en) 2014-08-14 2016-02-18 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
TW201625304A (zh) 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
FI3236943T3 (fi) 2014-12-24 2023-04-27 Principia Biopharma Inc Koostumuksia ileo-jejunaaliseen lääkkeenantoon
US9139653B1 (en) * 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2016196298A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
WO2017059224A2 (en) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AU2017293423B2 (en) * 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US10927117B2 (en) 2016-08-16 2021-02-23 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
DK3500299T3 (da) * 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
TW202246347A (zh) * 2016-08-26 2022-12-01 英屬開曼群島商百濟神州有限公司 抗tim-3抗體及其用途
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
PE20191034A1 (es) 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
EP3612839A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
CN111801334B (zh) * 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2019157353A1 (en) 2018-02-09 2019-08-15 Beigene, Ltd. Immunotherapy for urothelial carcinoma
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
US20210000838A1 (en) 2018-03-21 2021-01-07 Mei Pharma, Inc. Combination therapy
CN113939289A (zh) 2019-06-10 2022-01-14 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
EP3981400A4 (en) 2019-06-10 2023-07-12 BeiGene Switzerland GmbH ORAL CAPSULE AND ITS METHOD OF PREPARATION
JP2022548212A (ja) * 2019-09-11 2022-11-17 ベイジーン リミテッド マルチチロシンキナーゼ阻害剤及び免疫チェックポイント阻害剤を含む組合せを用いた癌の治療

Also Published As

Publication number Publication date
NO2023045I1 (no) 2023-12-07
RS63571B1 (sr) 2022-10-31
CN112457403B (zh) 2022-11-29
AU2013400609A9 (en) 2020-03-05
US20220119524A1 (en) 2022-04-21
ES2792183T3 (es) 2020-11-10
CA2924172C (en) 2020-06-30
EP3702373A3 (en) 2020-11-11
CA2924172A1 (en) 2015-03-19
AU2013400609B2 (en) 2019-11-14
CN105531288A (zh) 2016-04-27
IL284258A (en) 2021-07-29
US9834606B2 (en) 2017-12-05
EP3044234A1 (en) 2016-07-20
ES2927567T3 (es) 2022-11-08
PL3044234T3 (pl) 2020-10-19
PT3702373T (pt) 2022-09-27
ZA201601953B (en) 2017-06-28
EP3702373A2 (en) 2020-09-02
CN107011441B (zh) 2020-12-01
CA3080200A1 (en) 2015-03-19
MX2016003292A (es) 2016-06-24
EP3044234B1 (en) 2020-03-04
DK3702373T3 (da) 2022-09-12
CN108715615A (zh) 2018-10-30
EP3044234A4 (en) 2017-08-09
CA3078121A1 (en) 2015-03-19
IL272867A (en) 2020-04-30
CN112457403A (zh) 2021-03-09
EP4130044A1 (en) 2023-02-08
RS63571B9 (sr) 2023-02-28
SG11201601844TA (en) 2016-04-28
AU2022204171A1 (en) 2022-07-07
HUE060420T2 (hu) 2023-02-28
US9988450B2 (en) 2018-06-05
EP3702373B9 (en) 2022-11-23
CN108715615B (zh) 2020-11-27
BR112016005408A2 (pt) 2018-01-16
US20150079109A1 (en) 2015-03-19
US10519235B2 (en) 2019-12-31
WO2015035606A1 (en) 2015-03-19
IL312577A (en) 2024-07-01
FR24C1001I1 (fr) 2024-02-23
AU2013400609A8 (en) 2016-07-21
US20180251551A1 (en) 2018-09-06
IL272867B (en) 2021-07-29
HK1217501A1 (zh) 2017-01-13
HRP20221262T1 (hr) 2022-12-09
JP2016533763A (ja) 2016-11-04
NL301252I2 (nl) 2024-01-04
SI3702373T1 (sl) 2022-11-30
US20210230274A1 (en) 2021-07-29
IL284258B2 (en) 2023-02-01
US20230303689A1 (en) 2023-09-28
US20200216535A1 (en) 2020-07-09
US20150315274A1 (en) 2015-11-05
CN107090041B (zh) 2018-11-16
EA201690567A1 (ru) 2016-08-31
BR112016005408A8 (pt) 2023-01-10
KR102100419B1 (ko) 2020-04-14
AU2013400609A1 (en) 2016-05-05
TW201538525A (zh) 2015-10-16
CY1125652T1 (el) 2024-02-16
AU2020201069B2 (en) 2022-03-24
US20180111995A1 (en) 2018-04-26
CN105531288B (zh) 2020-12-11
PT3044234T (pt) 2020-05-27
EP3044234B9 (en) 2020-08-26
IL296026A (en) 2022-10-01
AU2013400609B9 (en) 2020-03-05
AU2020201069A1 (en) 2020-03-05
IL296026B1 (en) 2024-06-01
HUE049281T2 (hu) 2020-09-28
JP6623353B2 (ja) 2019-12-25
US8735553B1 (en) 2014-05-27
IL284258B (en) 2022-10-01
CN107011441A (zh) 2017-08-04
HUS2300041I1 (hu) 2023-12-28
BR112016005408B1 (pt) 2023-03-21
LT3702373T (lt) 2022-11-10
CN112552401A (zh) 2021-03-26
IL244514B (en) 2020-03-31
PL3702373T3 (pl) 2022-12-05
EA034666B1 (ru) 2020-03-04
DK3044234T3 (da) 2020-05-18
CN107090041A (zh) 2017-08-25
EP3702373B1 (en) 2022-08-24
IL244514A0 (en) 2016-04-21
US9217034B2 (en) 2015-12-22
NZ718643A (en) 2020-02-28
TWI636995B (zh) 2018-10-01
US11186637B2 (en) 2021-11-30
KR20160044063A (ko) 2016-04-22
CY2023025I1 (el) 2024-02-16
US11673951B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
AU2020201069B2 (en) Anti-PD1 antibodies and their use as therapeutics and diagnostics
JP6800191B2 (ja) 抗ｐｄ−１抗体並びにその治療及び診断のための使用
EA044655B1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant